Track market-moving stories before they get noisy

Key Takeaways Albemarle paid down $1.3 billion of debt in March 2026, reducing annual interest expense by $60 million.Albemarle ended the second quarter with $1.88 billion of long-term debt and 0.5x net debt-to-EBITDA.Albemarle had $3.2 billion of liquidity and no major debt maturities until late 2028. Albemarle Corporation (ALB - Free Report) remains committed to paying down debt and strengthening its balance sheet. The company paid down $1.3 billion of outstanding debt in March 2026, reducing annual interest expense by roughly $60 million. This followed the successful divestments of the controlling stake in Ketjen and its 50% interest in the Eurecat joint venture, which together generated $670 million in pre-tax proceeds.

ALB’s total long-term debt was roughly $1.88 billion at the end of the second quarter, down from $3.19 billion at the end of 2025. The company ended the quarter with a net debt-to-EBITDA leverage ratio of 0.5x compared with 1x at the end of the sequentially prior quarter. It has no major maturities due until late 2028.

At the end of the second quarter, ALB had liquidity of around $3.2 billion, including cash and cash equivalents of around $1.6 billion. Its deleveraging efforts are expected to continue to result in improved balance sheet and financial flexibility while reducing interest expenses. Factoring in the debt reduction actions completed in the first quarter of 2026, ALB sees interest and financing expense to be in the band of $120-$140 million for 2026.

Among its peers, Sociedad Quimica y Minera de Chile S.A. (SQM - Free Report) exited the second quarter with long-term debt of around $4.79 billion. It had strong liquidity, with cash and cash equivalents of around $3.4 billion. Sociedad Quimica, in early December 2025, issued a hybrid bond for roughly $430 million to refinance debt and fund its investment plan.

ICL Group Ltd. (ICL - Free Report) ended the second quarter with outstanding net debt of roughly $2.64 billion, up $375 million from the end of 2025. Including unutilized revolving credit facility and securitization, ICL Group had cash resources of $2.2 billion at the end of the quarter. ICL completed a private offering of $800 million senior notes due 2036 and plans to use part of the net proceeds from the offering for the repayment, in part or in full, of outstanding borrowings under its revolving credit facility maturing in April 2030, and to repay other debt.

ALB’s Price Performance, Valuation & EstimatesAlbemarle has gained 15.3% over a year compared with the Zacks Chemical - Diversified industry’s decline of 3.3%.

Image Source: Zacks Investment Research

ALB is currently trading at a forward price-to-sales ratio of 1.96, above the industry. It carries a Value Score of B.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for ALB’s 2026 earnings implies a year-over-year rise of 1,541.8%. The EPS estimates for 2026 have been trending lower over the past 60 days.

Image Source: Zacks Investment Research

Central Pacific Bank Trust Division raised its position in Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM – Free Report) by 31.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,815 shares of the semiconductor company’s stock after acquiring an additional 2,336 shares during the period. Central Pacific Bank Trust Division’s holdings in Taiwan Semiconductor Manufacturing were worth $4,478,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of TSM. Brookstone Capital Management boosted its stake in shares of Taiwan Semiconductor Manufacturing by 87.3% in the 2nd quarter. Brookstone Capital Management now owns 25,143 shares of the semiconductor company’s stock valued at $12,008,000 after purchasing an additional 11,719 shares in the last quarter. Y Intercept Hong Kong Ltd increased its position in shares of Taiwan Semiconductor Manufacturing by 273.2% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 81,189 shares of the semiconductor company’s stock worth $27,438,000 after purchasing an additional 59,435 shares in the last quarter. Opal Capital LLC lifted its holdings in Taiwan Semiconductor Manufacturing by 72.5% during the 1st quarter. Opal Capital LLC now owns 27,767 shares of the semiconductor company’s stock valued at $9,384,000 after purchasing an additional 11,666 shares during the last quarter. Western Wealth Management LLC lifted its holdings in Taiwan Semiconductor Manufacturing by 27.4% during the 1st quarter. Western Wealth Management LLC now owns 27,954 shares of the semiconductor company’s stock valued at $9,447,000 after purchasing an additional 6,013 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC boosted its position in Taiwan Semiconductor Manufacturing by 306.7% in the first quarter. Elevation Point Wealth Partners LLC now owns 52,397 shares of the semiconductor company’s stock valued at $17,728,000 after buying an additional 39,514 shares in the last quarter. Institutional investors own 16.51% of the company’s stock.

Analyst Upgrades and Downgrades Several research firms have recently weighed in on TSM. Barclays raised their price objective on shares of Taiwan Semiconductor Manufacturing from $625.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Stifel Nicolaus assumed coverage on Taiwan Semiconductor Manufacturing in a report on Tuesday, September 1st. They issued a “buy” rating and a $515.00 target price on the stock. Sanford C. Bernstein increased their price target on Taiwan Semiconductor Manufacturing from $430.00 to $554.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 11th. Zacks Research raised Taiwan Semiconductor Manufacturing from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. Finally, Weiss Ratings upgraded Taiwan Semiconductor Manufacturing from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, September 22nd. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $523.22.

Read Our Latest Research Report on TSM Here are the key news stories impacting Taiwan Semiconductor Manufacturing this week:

Positive Sentiment: Elon Musk confirmed early discussions with TSMC regarding “Terafab,” a proposed Texas chip-manufacturing venture intended to serve Tesla, SpaceX and xAI. Although no agreement has been announced, investors view the talks as a potential source of long-term demand and a validation of TSMC’s manufacturing expertise. Musk confirms talks with TSMC over Terafab chip plant Positive Sentiment: TSMC’s shares broke to a new 52-week high after the Terafab news, reinforcing bullish momentum in the stock and highlighting investor enthusiasm for additional U.S. manufacturing opportunities. Taiwan Semiconductor gains to record as Musk confirms Terafab talks Positive Sentiment: Investors expect strong revenue growth in the October 15 earnings release, supported by record monthly sales and sustained demand for advanced chips used in artificial intelligence. The launch of 2-nanometer production is viewed as an important future growth catalyst. TSMC is set up for a big October 15 Neutral Sentiment: Analysts and investors continue to view TSMC as a key supplier to Nvidia, Apple and the broader AI industry. However, its growth rate may be slower than some AI-focused peers, making the upcoming earnings outlook and guidance especially important. Is Taiwan Semiconductor the best AI stock to buy now? Negative Sentiment: The key risk ahead of earnings is margin pressure. Ramping 2nm production and expanding overseas factories could initially carry higher costs and lower margins, challenging the premium valuation investors have placed on TSMC. How much overseas factory cost can TSMC’s valuation absorb? Taiwan Semiconductor Manufacturing Stock Performance Shares of Taiwan Semiconductor Manufacturing stock opened at $486.04 on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.46 and a quick ratio of 2.25. The firm has a 50 day simple moving average of $427.31 and a 200 day simple moving average of $410.67. Taiwan Semiconductor Manufacturing Company Ltd. has a fifty-two week low of $266.82 and a fifty-two week high of $487.47. The firm has a market cap of $2.52 trillion, a P/E ratio of 35.07, a P/E/G ratio of 1.05 and a beta of 1.37.

Taiwan Semiconductor Manufacturing (NYSE:TSM – Get Free Report) last announced its quarterly earnings data on Tuesday, June 30th. The semiconductor company reported $4.28 EPS for the quarter. The firm had revenue of $39.89 billion for the quarter. Taiwan Semiconductor Manufacturing had a return on equity of 39.25% and a net margin of 50.31%. Sell-side analysts predict that Taiwan Semiconductor Manufacturing Company Ltd. will post 16.56 earnings per share for the current fiscal year.

Taiwan Semiconductor Manufacturing Cuts Dividend The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 7th. Shareholders of record on Thursday, December 10th will be given a dividend of $1.0854 per share. This represents a $4.34 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Thursday, December 10th. This is a drop from Taiwan Semiconductor Manufacturing’s previous quarterly dividend of $1.1136. Taiwan Semiconductor Manufacturing’s dividend payout ratio is currently 24.75%.

Insider Activity In other Taiwan Semiconductor Manufacturing news, VP Bor-Zen Tien acquired 3,000 shares of Taiwan Semiconductor Manufacturing stock in a transaction on Tuesday, July 21st. The shares were purchased at an average cost of $74.39 per share, with a total value of $223,170.00. Following the completion of the purchase, the vice president owned 4,000 shares in the company, valued at $297,560. The trade was a 300.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Shyue-Shyh Lin bought 2,000 shares of the stock in a transaction on Sunday, July 19th. The shares were acquired at an average cost of $71.71 per share, with a total value of $143,420.00. Following the acquisition, the vice president directly owned 28,269 shares in the company, valued at approximately $2,027,169.99. This trade represents a 7.61% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have acquired 14,559 shares of company stock valued at $1,067,931. 1.11% of the stock is currently owned by insiders.

Taiwan Semiconductor Manufacturing Company Profile (Free Report)

Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM), commonly known as TSMC, is a Taiwan-based semiconductor manufacturer and the world’s largest dedicated semiconductor foundry. Founded in 1987 by Morris Chang, the company pioneered the pure-play foundry model, producing chips designed by other companies rather than selling products under its own semiconductor brand.

TSMC manufactures a broad range of integrated circuits, including advanced logic chips used in high-performance computing, smartphones, automotive systems, communications equipment, and consumer electronics.

Further Reading Five stocks we like better than Taiwan Semiconductor Manufacturing NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run A Manufacturing Surprise Could Be a Big Win for These 2 Companies What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks

Receive News & Ratings for Taiwan Semiconductor Manufacturing Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taiwan Semiconductor Manufacturing and related companies with MarketBeat.com's FREE daily email newsletter.

ServiceNow's AI business is accelerating while its stock sits near a 52-week low, and that disconnect has our model flagging an opportunity most investors are pricing wrong.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Our 24/7 Wall St. price target for ServiceNow (NYSE:NOW | NOW Price Prediction) is $238.73 over the next 12 months. With shares at $135.85, that means 75.7% upside. Our model rates the stock a buy with high confidence.

24/7 Wall St. Price Target Summary Metric Value Current Price $135.85 Price Target from 24/7 Wall St. $238.73 Upside/Downside 75.7% Recommendation BUY Confidence Level 90% The market has punished ServiceNow for acquisition-driven GAAP margin compression. Meanwhile, the AI business is speeding up.

ServiceNow AI passed $1B in annual contract value, and the stock trades at 28x forward earnings. Our model sees that gap closing, which is why ServiceNow could be a much bigger company by 2028.

A 26% One-Year Slide Has Reset ServiceNow’s Valuation Shares are down 3.5% over the past week, 8.2% over the past month, 11.32% year to date and 26.19% over the past year. The stock sits 29.6% below its 52-week high of $192.97 and 67.2% from its low of $81.24.

Fundamentals keep improving even as the share price falls behind. Second-quarter non-GAAP EPS of $0.90 exceeded the $0.86 consensus.

Revenue rose 24% to $3.987B, and management raised full-year subscription guidance to $15.76B to $15.78B. MarketWatch this week named ServiceNow among the tech stocks that could lead the next leg of the AI trade.

Why Bulls See $264 Within a Year The bull case lands at $264.44. Management said the company is on track to beat its $1.5 billion AI ACV target by end of 2026. Customers running agentic AI in production rose 9x in nine months. Deals above $1 million in net new ACV grew 40% to 123. Renewal rate held at 98%.

Management’s long-term goal is $30B+ in subscription revenue by 2030. CEO Bill McDermott called this “the foundation for a re-rating of ServiceNow.”

Of analysts covering the stock, 10 rate it a strong buy and 35 a buy, with a consensus target of $144.99.

Stifel analyst Brad Reback raised the firm’s price target on ServiceNow to $160 from $120 and keeps a buy rating on the shares while UBS raised the firm’s price target on the stock to $150 from $110 and keeps a Neutral rating on the shares. 

What Could Derail the AI Re-Rating GAAP operating income fell 54.75% to $162M, and GAAP subscription gross margin slipped to 73.5% from 80%. Over the past 30 days, analysts made 29 down revisions to 2026 EPS estimates versus 9 up.

Our bear case is $189.05. Most margin decline comes from amortization of acquired intangibles tied to Armis, expected to normalize in FY27. Free cash flow rose 20.53% to $634M.

Investors looking at ServiceNow’s AI monetization story often miss the companies providing the picks and shovels for the broader expansion (we rounded up seven of those non-chipmaker winners in a free report you can grab here).

ServiceNow Outgrows Salesforce and Workday Salesforce (NYSE:CRM) competes directly for spending on agentic AI. The stock trades at 25x earnings, but its revenue grew only 10.83%. That earnings figure is also inflated by $2,613 million in gains on strategic investments.

Workday (NASDAQ:WDAY) is ServiceNow’s closest match in workflow software, and its revenue grew 12.82% at 54x earnings.

Company P/E Latest Quarterly Revenue Growth ServiceNow 81x trailing / 28x forward 24.0% Salesforce 25x 10.83% Workday 54x 12.82% ServiceNow’s revenue is growing about twice as fast as either peer’s, and its forward multiple sits close to Salesforce’s trailing one. Against that background, our target looks reasonable.

ServiceNow Price Prediction 2026-2030 The 24/7 Wall St. price target of $238.73 has a buy rating and 90% confidence. What tips the scale is AI monetization that is growing faster than expected.

The thesis strengthens if AI ACV tops $1.5 billion by year-end. It weakens if GAAP margins keep falling after FY27. At 28x forward earnings, the model sees reward outweighing risk.

Our model projects where ServiceNow could trade, assuming current growth trends hold.

Year Price Target from 24/7 Wall St. 2026 $154.82 2027 $238.73 2028 $356.82 2029 $434.78 2030 $529.78 ServiceNow would need to keep executing on its AI and security strategy for these estimates to hold. Results could beat or miss these figures by a wide margin depending on how fast AI ACV grows and how smoothly the Armis integration goes.

Contact [email protected] for any questions or corrections.

Broadcom's AI revenue is exploding at triple-digit growth rates, yet the stock has barely moved in 2025. Something has to give, and figuring out which way it breaks could make or break your 2028 portfolio.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Broadcom (NASDAQ:AVGO | AVGO Price Prediction | AVGO Price Prediction) just reported a standout quarter. Fiscal Q3 revenue reached $29.59 billion, up 85.5% YoY. AI semiconductor revenue hit $16.7 billion, up 221%.

CEO Hock Tan said, “Demand for our custom AI accelerators and networking continues to be very strong.” Even so, the stock is up only 0.72% this year.

I see that gap as the central question for investors. This article asks one question: can Broadcom hit $550 per share in 2028?

What’s Holding Broadcom Back Right Now The stock traded at $371.27 on Sept. 2 and has fallen since, down 6.22% over the past month.

Three issues weigh on it: management guided consolidated gross margin down to about 74% due to product mix; the company relies on a small number of large AI customers; and with a beta of 1.46, Broadcom moves more sharply than the market when AI enthusiasm cools off. The stock needs new evidence to move higher.

Wall Street Sees 51.4% Upside. Our Model Says 20.7% The consensus price target sits at $531.85, suggesting 51.4% upside. Analyst ratings stand at 8 Strong Buy, 37 Buy, 4 Hold and 0 Sell. Our model is more conservative.

Its one-year base case lands at $423.79, or 20.67% upside, within a range of $374.67 (bear case) to $532.91 (bull case). The model’s confidence score of 0.9 means it has high conviction in that range.

On this one, I side with the Street. 92% of analysts are bullish, and earnings growth adds 0.03 to the model, which labels it “strong earnings acceleration.” Management also says its visibility now runs “all the way to 2028.”

Here’s What It Takes for Broadcom to Reach $550 Reaching $550 from $351.19 means a rise of 56.6%. At forward EPS of $18.3613, a $550 share price implies a forward P/E of 30x, about 6x below the model’s implied 36x. The rerating needed is a move from today’s multiple to 30x.

The model’s adjustment factor of 1.146 comes from a 1.15 sector momentum multiplier and strong analyst consensus, partly offset by a 50% mega-cap penalty. Earnings growth is contracting the multiple: trailing P/E is 46x, forward P/E is 19x.

Q4 guidance calls for AI revenue of $21.7 billion, up 236%. Management expects fiscal 2027 AI revenue “in excess of $100 billion.” Barron’s reported Anthropic and Broadcom are becoming more intertwined.

CEO Tan: “Demand for XPUs and networking is simply insatiable.” The main risk: Alphabet (NASDAQ:GOOGL) unit Google plans some diversity of sources for chips, potentially limiting the multiple.

Where Broadcom Trades Today vs Its Earnings Power Broadcom trades at 19x forward earnings, a low multiple for a company growing revenue at 85.5%. The stock sits between its 52-week low of $288.95 and high of $493.28.

Over 10 years, it has returned 2,482.49%. At today’s multiple, the market prices in little of the 2027 AI ramp, the core of the optimistic thesis.

Can Broadcom Really Hit $550? My Verdict Hitting $550 requires a 56.6% gain. I consider it reachable. Our 2028 bull case reaches $624.06 by October 2028. Three things must go right:

AI revenue passes $100 billion in fiscal 2027. Gross margin stabilizes. OpenAI and Meta Platforms (NASDAQ:META) deployments ship on schedule. A spending pullback by a major hyperscaler could disrupt the target. Such gains are rare in any single year, and we’ve outlined the path for how Broadcom could reach $550 in 2028. The signs that showed up in past AI-chip winners before their monster runs are the ones we cataloged in a free playbook here.

Contact [email protected] for any questions or corrections.

Central Pacific Bank Trust Division grew its stake in shares of Spotify Technology (NYSE:SPOT – Free Report) by 28.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,760 shares of the company’s stock after purchasing an additional 1,063 shares during the quarter. Central Pacific Bank Trust Division’s holdings in Spotify Technology were worth $2,320,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Montanova Capital LLC boosted its holdings in shares of Spotify Technology by 9,154.5% during the second quarter. Montanova Capital LLC now owns 101,800 shares of the company’s stock worth $46,739,000 after purchasing an additional 100,700 shares during the period. Sycale Advisors NY LLC increased its holdings in Spotify Technology by 89.6% during the 4th quarter. Sycale Advisors NY LLC now owns 36,075 shares of the company’s stock valued at $20,949,000 after purchasing an additional 17,050 shares during the period. HS Management Partners LLC bought a new position in Spotify Technology during the 2nd quarter valued at approximately $13,404,000. Ally Financial Inc. raised its position in Spotify Technology by 100.0% during the 2nd quarter. Ally Financial Inc. now owns 7,000 shares of the company’s stock valued at $3,214,000 after purchasing an additional 3,500 shares during the last quarter. Finally, Plato Investment Management Ltd purchased a new stake in Spotify Technology in the 2nd quarter worth approximately $1,363,000. Institutional investors own 84.09% of the company’s stock.

Analyst Ratings Changes Several equities analysts have recently issued reports on the company. Wells Fargo & Company reduced their target price on Spotify Technology from $600.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday, July 9th. Cantor Fitzgerald lifted their price target on shares of Spotify Technology from $510.00 to $530.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. UBS Group decreased their price objective on shares of Spotify Technology from $690.00 to $675.00 and set a “buy” rating for the company in a report on Monday. Wall Street Zen cut shares of Spotify Technology from a “buy” rating to a “hold” rating in a research report on Saturday, July 25th. Finally, Benchmark cut their target price on shares of Spotify Technology from $695.00 to $650.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $592.75.

View Our Latest Stock Analysis on SPOT Spotify Technology Stock Up 2.1% NYSE SPOT opened at $482.92 on Tuesday. The firm has a market capitalization of $99.42 billion, a PE ratio of 30.07, a P/E/G ratio of 1.45 and a beta of 1.61. The stock’s 50 day moving average is $517.61 and its 200 day moving average is $493.27. Spotify Technology has a twelve month low of $405.00 and a twelve month high of $700.12.

Spotify Technology (NYSE:SPOT – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $3.03 earnings per share for the quarter, missing analysts’ consensus estimates of $3.16 by ($0.13). Spotify Technology had a return on equity of 41.39% and a net margin of 18.44%.The business had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.47 billion. During the same quarter last year, the company posted ($0.42) EPS. Spotify Technology’s revenue for the quarter was up 13.9% compared to the same quarter last year. On average, research analysts anticipate that Spotify Technology will post 13.85 earnings per share for the current year.

Trending Headlines about Spotify Technology Here are the key news stories impacting Spotify Technology this week:

Positive Sentiment: UBS maintained a constructive outlook and said Spotify is expected to continue progressing toward its financial targets despite increased platform-investment costs. The bank believes new products and features can create more monetization opportunities and improve operating leverage. Its AI-powered Remix tool could launch by late 2026 or early 2027. Spotify expected to make progress towards financial targets, UBS says Positive Sentiment: UBS retained a Buy rating, indicating it still sees substantial long-term upside for SPOT. The investment case centers on differentiated products, feature innovation and stronger monetization of Spotify’s large user base. Spotify’s Differentiated Products Support Additional Monetization Opportunities Neutral Sentiment: UBS lowered its price target from $690 to $675 while keeping the Buy rating. The reduction reflects some caution around investment-related costs, but the revised target still implies meaningful upside relative to the referenced trading level. Neutral Sentiment: Spotify’s marketing and brand-engagement initiatives are drawing attention ahead of earnings. Analysts expect revenue growth but are also watching for a possible decline in earnings per share, making profitability and conversion of user engagement key investor issues. Is Spotify Prioritizing Brand Engagement Over Profit Discipline As Earnings Expectations Shift? Negative Sentiment: Consumer-demand commentary suggested some listeners may be favoring Apple Music over Spotify, raising concerns about competitive pressure and potential slowing engagement growth. A sustained shift toward Apple could weigh on subscriber growth, pricing power and monetization. Consumers Tuning Out SPOT in Favor of AAPL Insider Buying and Selling at Spotify Technology In related news, CEO Alex Norström sold 5,436 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $502.10, for a total transaction of $2,729,415.60. Following the sale, the chief executive officer directly owned 66,773 shares of the company’s stock, valued at approximately $33,526,723.30. This represents a 7.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Gustav Söderström sold 20,913 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $544.19, for a total transaction of $11,380,645.47. Following the sale, the chief executive officer owned 20,025 shares of the company’s stock, valued at approximately $10,897,404.75. This represents a 51.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 47,182 shares of company stock valued at $24,677,392 over the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Spotify Technology Company Profile (Free Report)

Spotify Technology SA is a global audio streaming company that operates the Spotify platform. The service provides users with access to a broad catalog of music, podcasts and audiobooks, along with personalized recommendations, playlists and other discovery features.

Spotify offers a subscription-based Premium service with enhanced listening features, as well as an ad-supported service available at no direct cost to users. The company generates revenue primarily through Premium subscriptions and advertising, including audio, video and display advertising delivered across its platform.

Founded in 2006 by Daniel Ek and Martin Lorentzon, Spotify is headquartered in Stockholm, Sweden, and serves listeners, creators, advertisers and other partners across markets worldwide.

Featured Articles Five stocks we like better than Spotify Technology NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run A Manufacturing Surprise Could Be a Big Win for These 2 Companies What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks Want to see what other hedge funds are holding SPOT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spotify Technology (NYSE:SPOT – Free Report).

Receive News & Ratings for Spotify Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spotify Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways XOM and SU argue federal law should block Boulder's climate claims from moving ahead in state court.A 4-4 Supreme Court split would leave Colorado's ruling intact without creating a nationwide precedent.Nearly 60 state and local governments have filed similar climate cases seeking billions in damages. The U.S. Supreme Court opened its new term by hearing arguments in a climate case involving the city and county of Boulder, CO, ExxonMobil Holdings (XOM - Free Report) and Suncor Energy (SU - Free Report) . Boulder’s city and county governments sued the two companies under state law, seeking compensation for costs they link to climate change, including damage tied to wildfires, droughts, floods, infrastructure repairs and public-health effects. Boulder also alleges that ExxonMobil and Suncor misled the public about the risks associated with fossil fuels. The companies deny the allegations.

The case began in 2018 and has spent years moving through the courts. Colorado’s Supreme Court allowed the lawsuit to continue in state court. ExxonMobil and Suncor then asked the U.S. Supreme Court to intervene. The main question now is whether federal law prevents Boulder from pursuing these claims under Colorado law.

What ExxonMobil and Suncor Are ArguingExxonMobil and Suncor argue that climate change is national and international in scope, so claims involving greenhouse-gas emissions should be handled under federal law rather than through individual state courts. Their lawyers contend that federal environmental law, including the Clean Air Act, prevents lawsuits such as Boulder’s from going forward under state law.

The companies have also warned about the wider effect of allowing the case to proceed. Similar climate lawsuits have been filed by state and local governments around the country. According to ExxonMobil and Suncor, nearly 60 state and local governments have brought such cases, with plaintiffs seeking billions of dollars in damages. The companies say allowing Boulder’s claims to continue could leave energy producers facing many separate lawsuits under different state laws.

How Boulder Sees the DisputeBoulder says its lawsuit is not an attempt to set emissions policy. Instead, local officials say they are seeking money for alleged damage and costs tied to the companies’ conduct and marketing. Boulder argues that state courts regularly hear cases involving companies based elsewhere when their products or actions allegedly cause harm inside the state.

Several justices questioned both sides during the hearing. Some asked why claims involving alleged marketing deception should automatically be blocked by federal law. Others raised concerns about what would happen if municipalities across the country filed similar cases. The discussion also touched on earlier lawsuits involving tobacco and opioid companies, although ExxonMobil and Suncor argued that those cases involved a more direct connection between the product and the alleged harm.

Why the Supreme Court Decision MattersJustice Samuel Alito recused himself, leaving eight justices to decide the case. That creates the possibility of a 4-4 split. If that happens, the Colorado Supreme Court ruling would remain in place and Boulder’s lawsuit could continue, but the split would not create a nationwide Supreme Court precedent.

A broader ruling for Zacks Rank #3 (Hold) ExxonMobil and Zacks Rank #1 (Strong Buy) Suncor could affect dozens of other climate cases brought around the United States. A ruling allowing Boulder to proceed would not decide whether the companies are ultimately liable. It would mainly determine whether the claims can continue through the state-court process. You can see the complete list of today’s Zacks #1 Rank stocks here.

For investors following ExxonMobil and Suncor, the immediate issue is the path of the litigation rather than an existing damages award. The Supreme Court has not yet decided the case, and questions during oral arguments did not point to a clear outcome. A ruling is expected by the end of June 2027.

 | Source: Canadian National Railway Company

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) will issue its third-quarter 2026 financial and operating results before the markets open on October 30, 2026.

CN's senior officers will review the results and the railway's outlook in a conference call starting at 8:30 a.m. Eastern Time on October 30. Tracy Robinson, CN President and Chief Executive Officer, will lead the call.

Parties wishing to participate via telephone may dial 1-800-715-9871 (Canada/U.S.), or 1-647-932-3411 (International), using 5186426 as the passcode. Participants are advised to dial in 10 minutes prior to the call.

CN will webcast the presentation live and furnish slides supporting the officers' remarks via the Investors section of its website at www.cn.ca/investors. A webcast replay will be available after the call ends.

About CN
CN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada’s Eastern and Western coasts with the U.S. Midwest and the U.S. Gulf Coast, contributing to sustainable trade and the prosperity of the communities in which it operates since 1919.

Contacts:
   MediaInvestment CommunityAshley MichnowskiJamie LockwoodSenior ManagerVice-PresidentMedia RelationsInvestor Relations & Special Projects(438) 596-4329(514) 399-0052
[email protected]@cn.ca

By connecting information about each person's health, care and coverage, Health Sense℠ helps people receive continuous personalized support, make informed decisions and act sooner

Projected to reduce inefficient health care spending by 10% by 2030, improving affordability for employers and customers alike. Watch a demonstration of the new Health Sense customer experience. , /PRNewswire/ -- Cigna Healthcare, the health benefits division of The Cigna Group (NYSE: CI), today introduced Health Sense℠, a personalized customer and clinical support model that connects information about a person's health, care, benefits, costs and previous interactions. Health Sense is designed to improve health outcomes and affordability by helping people receive support sooner, make informed decisions with their treating clinician and take the next step.

See how Health Sense carries relevant context across customer interactions.

Health Sense connects context across digital, care management and clinical interactions.

Health Sense builds on Cigna Healthcare’s digital, customer support, care management and clinical capabilities, along with advanced reasoning technology from The Cigna Group. Experience the full interactive Multichannel News Release here: https://www.multivu.com/cigna/9373952-en-cigna-healthcare-introduces-health-sense-personalized-customer-clinical-support-model

Approximately one-third of health care spending is inefficient, driven by duplicative or unnecessary care, administrative complexity, poor coordination and missed opportunities to help people get care at the right time. By helping people act earlier and make better use of their benefits, Health Sense is projected to reduce 10% of this inefficient spending by 2030, lowering costs and improving affordability for customers and their employers.

Health care information, benefits and support are often spread across systems that do not connect, requiring people to navigate multiple sources, make decisions without cost information, and determine what help is available. Health Sense brings those pieces together around each person, connecting them with relevant context based on their circumstances.

Building on previous interactions to create a fuller picture of each person's needs and circumstances, Health Sense carries relevant context from one interaction to the next, helping customers move forward without having to repeat their story.

Health Sense is embedded across the Cigna Healthcare experience that customers already use rather than operating as a one-size-fits-all chatbot or standalone app. It is also grounded in clinically validated information and expertise from Cigna Healthcare physicians, nurses, pharmacists, behavioral health specialists and care management teams. Together, these resources help people understand their options and take informed next steps in support of the treatment plan established by their treating provider.

"Health care becomes harder and often more costly when people must navigate disconnected information, benefits and support on their own," said Bryan Holgerson, president of Cigna Healthcare U.S. and executive vice president of customer health outcomes at The Cigna Group. "Health Sense is designed to create a more complete view of each person's needs and circumstances, connecting people to relevant support sooner through a continuous, personalized experience that helps employers get more value from their health care investments."

From disconnected interactions to a connected path forward

A person managing a new diagnosis may need to piece together clinical guidance from multiple doctors, find an in-network provider, evaluate costs, use available benefits and connect with additional support.

Research commissioned by Evernorth, The Cigna Group's health services business, found that six in 10 Americans are not confident they understand all the health and wellness benefits available through their employer or health plan. Fifty-six percent said navigating care, benefits and vendor offerings is frustrating.

These challenges can be especially consequential for people with complex health needs who must coordinate multiple providers, services and decisions. Health Sense is designed to make the information, benefits and support available through Cigna Healthcare more relevant and easier to use.

"Data provides signals, but context gives those signals meaning," said Dr. Stanley Crittenden, chief medical officer at Cigna Healthcare. "Health Sense combines that context with clinical expertise to help tailor support to the person, the decision and the moment. That fuller picture helps our clinical and care teams recognize potential needs earlier, connect people with relevant resources and make it easier for them to move from information to action with their treating providers."

Support will vary based on a person's needs. For someone navigating cancer, Health Sense may provide a more seamless connection to a case manager. For someone managing a cardiometabolic condition, it may help identify and address medication adherence needs.

Three ways Health Sense creates a more personalized, continuous experience:

Context unique to each person. Health Sense connects available information about a person's health needs, benefits, pharmacy coverage, costs and previous interactions with Cigna Healthcare. This may include medical, behavioral health and pharmacy claims when Cigna or an affiliated company administers those services. The combined context helps digital experiences and care teams tailor support to a person's needs and available benefits. Clinical expertise with greater context. Health Sense provides relevant context to Cigna Healthcare clinical and care teams, helping them personalize support and collaborate more effectively with a person's treating provider to complement an existing treatment plan. It does not diagnose conditions, prescribe or modify treatment, or replace a treating provider. Treatment decisions remain between customers and their treating providers. Meaningful next steps. Health Sense helps people know their options, expected costs and available support; find appropriate in-network care; and prepare for appointments. Clearer choices can help people use their benefits more effectively and identify cost-conscious options when appropriate. This helps avoid unnecessary or duplicative costs, supporting greater affordability for customers and employers alike. Built on existing Cigna Healthcare services

Health Sense builds on Cigna Healthcare's award-winning myCigna digital platform, clinical expertise, established care management programs and advanced reasoning capabilities developed through The Cigna Group's technology investments.

Results from existing Cigna Healthcare programs deliver improved health engagement and greater affordability for both employers and the people that use their health plans:

Provider engagement that was 44% to 80% higher, depending on the program. $5,851 in annual savings among customers who met oncology care management goals. A 37% increase in colorectal cancer screenings. Engagement with diabetes prevention solutions that was 3.4 to 5.3 times higher. Availability

Cigna Healthcare will begin rolling out Health Sense in early 2027, initially for customers with oncology and cardiometabolic health needs. Support will vary based on each customer's circumstances, available benefits and care needs. Any clinical support is intended to complement, not replace, care and treatment from the customer's treating provider.

Evernorth Research Institute analyses found that cancer diagnoses and costs are rising among working-age adults and that progression of cardiometabolic conditions can increase total cost of care by at least 42% in one year. Cigna Healthcare selected these areas for the initial rollout because customers often must coordinate multiple providers, services and decisions.

Cigna Healthcare expects to expand Health Sense to additional customers, conditions, programs and services over time as the company measures outcomes.

FAQ: Health Sense by Cigna Healthcare: How it works, AI, clinical support and availability

About Cigna Healthcare

Cigna Healthcare is a health benefits provider that advocates for better health through every stage of life. We guide our customers through the health care system, empowering them with the information and insight they need to make the best choices for improving their health and vitality. Products and services are provided exclusively by or through operating subsidiaries of The Cigna Group (NYSE: CI), including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Health companies or their affiliates, and Express Scripts companies or their affiliates. Such products and services include an integrated suite of health services, such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits, and others.

Learn more at www.cignahealthcare.com.

Media Contact:
Gena Madow
[email protected]

SOURCE Cigna Healthcare

Exclusive

By You're currently following this author! Click to unsubscribe from email alerts.

David Ellison is CEO of Skydance after Paramount merged with Warner Bros. Discovery. Paul Morigi/Getty Images; David Becker/Getty Images for CinemaCon David Ellison is taking a victory lap after completing Paramount's merger with Warner Bros. Discovery, forming the new-look Skydance.

"It has taken hard work, perseverance and commitment with many challenges along the way — but we did it!" Ellison said in a memo to employees on Tuesday morning, which was obtained by Business Insider.

Ellison expressed thanks to staffers across Paramount and WBD for "your patience, your resilience and, above all, your belief in what we could accomplish together."

Skydance will be "powered by creativity and technology," Ellison said, adding that the company has four top priorities:

Win in storytelling.Become the most technologically capable media company.Lead in a crowded market.Earn Trust Every Day. ELF chief brand officer Laurie Lam talks the importance of diverse boardrooms

"Audiences have more choices than ever, technology is reshaping how stories are created, distributed and experienced, and competition for people's time and attention has never been greater," Ellison said in his memo. "We don't just want to succeed in this environment — we want to win and help shape the future of the industry."

Read the full memo from Ellison and co-CEO Ynon Kreiz to Skydance employees here:

Team,Today we begin an exciting new chapter as Skydance.Getting here has been quite a journey. Over the past year and beyond, it has taken hard work, perseverance and commitment with many challenges along the way — but we did it! To everyone at both companies who helped get us to this moment: thank you. Thank you for your patience, your resilience and, above all, your belief in what we could accomplish together.Bringing Paramount and Warner Bros. Discovery together fulfills a vision that began with Skydance's acquisition of Paramount: to build the next-generation media and entertainment company, powered by creativity and technology. The goal was never simply to add more production capacity, brands or IP. It was to unite the talent, resources and capabilities of these companies into a stronger competitor, one with the scale to take on the biggest players in our industry. Together, we will give these iconic studios the opportunity to win for generations to come.Built for what's aheadAs all of you know, our industry is in a period of profound change. Audiences have more choices than ever, technology is reshaping how stories are created, distributed and experienced, and competition for people's time and attention has never been greater. We don't just want to succeed in this environment — we want to win and help shape the future of the industry.We want to lead.And that starts with what we're building together: a company that tells great stories in every genre, for audiences everywhere, on every platform. A company that can compete in a crowded market and win at global scale, create enduring value for all stakeholders, and strengthen the industry as a whole.As owner-operators, we're in this for the long term, committed to building Skydance for the future — not simply optimizing for the next quarter or the next year, but creating a company built to endure, evolve and remain relevant. That means being creative-first, audience-focused, tech-forward and globally scaled — building a thriving ecosystem where stories and worlds are imagined, brought to life and experienced by audiences of all ages, everywhere.At the center of it all is a clear purpose: to entertain, inspire and inform the world through extraordinary storytelling. And we'll be guided every step of the way by shared priorities that shape how we intend to operate, how we make decisions, how we work together and how we show up for our audiences, our partners and one another.Our top prioritiesTo bring that mission to life, these are the priority areas where we will concentrate our energy:Win in storytelling.
Great stories remain at the heart of everything we do. We will invest in the ideas, creators, franchises and experiences that captivate audiences around the world and create lasting cultural impact. On the big screen, we are committed to making at least 30 movies a year, pairing original stories from today's most exciting filmmakers with beloved franchises like Harry Potter, Mission: Impossible, The Lord of the Rings, DC, Transformers and Star Trek. On television and streaming, it means storytelling like Game of Thrones, Landman, NCIS, Tracker and SpongeBob SquarePants. In games, it means worlds like Hogwarts Legacy and Mortal Kombat; and in live sports, it means the NFL on CBS, the UFC, UEFA and March Madness, just to name a few. Become the most technologically capable media company.
Technology is fundamentally reshaping our industry, and we intend to be at the forefront. We will use technology, data and emerging capabilities to improve how we create, distribute and monetize content, from new production tools to personalization and entirely new ways for fans to engage with the stories they love. We will embrace the opportunities AI provides to expand what our creatives can imagine and to make our businesses even more productive. The opportunities ahead are enormous, and we intend to seize them. But one principle will never change: technology must serve the art — never the other way around.
Lead in a crowded market.
We came together to create another major competitor in the industry. And with our combined scale, assets and global reach, we are positioned to take on some of the largest technology and media companies in the world and to lead in an evolving entertainment landscape. We will use that strength to drive synergies, operate with discipline and invest in the long-term growth of our business. And we will go further than traditional synergies. By embracing the most advanced technologies available and embedding them into how we operate, we will work smarter, move faster and unlock efficiencies the merger alone could not deliver.
Earn Trust Every Day.
Trust is foundational to everything we do. And we are committed to earning it every day by communicating directly, following through on our commitments and listening closely to those we serve and work alongside. That is essential to our reputation and our long-term success.
As we work toward these goals, we must never lose sight of what matters most: our people. We will build a culture where people feel respected, empowered, supported and proud of the work they do. And we will extend that same commitment, with reliability and responsibility, to our creators, audiences, consumers, advertisers and partners.None of what we accomplish happens in a vacuum. It reflects everyone joining forces to unlock the full potential of our assets: an unmatched portfolio of brands, franchises, libraries, IP and creative talent, with decades of history and, in many cases, decades of opportunity still ahead.Together, we can reach audiences across platforms, markets, and generations in ways neither Paramount nor WBD could have achieved alone. With the talent, scale, relationships and resources to build on, we can create something truly distinctive.For audiences, it means more choice and more ways to experience the stories they love. For creators, it means a partner with the scale and capabilities to help their best ideas reach the widest possible audience. For our partners, it means a broader, more powerful platform to build on. And for the broader creative community, it means an enduring commitment to storytelling and the people who make it possible.That is the foundation of Skydance. And it's why this combination matters so much.Honoring an extraordinary legacyThe union of these two iconic companies represents an exciting future. But, just as important as what we build together is preserving what has made them iconic in the first place. Paramount and Warner Bros. each have a distinct identity and extraordinary legacy that deserves to stand on its own.In choosing our corporate brand, we never wanted to diminish, alter or overshadow any of the assets that have global recognition and have withstood the test of time. Both studios will continue to operate under their own names, and audiences will still see the Paramount mountain and the Warner Bros. shield before the films and shows they love.Warner Bros. is woven into the history of modern entertainment, from film and television to journalism, sports, unscripted programming and some of the world's most recognizable characters and franchises. Paramount has an equally extraordinary legacy, with more than a century of storytelling that helped define the American film industry and shape entertainment across every medium.We realized early on that simply combining the two names — WarnerParamount, ParaWarner or ParamountWarner — accomplished none of what we wanted. Every variation somehow made two giants feel smaller, not greater. It asked each to give something up rather than allowing us to create something new. This isn't a merger of convenience. It's the beginning of a new era in entertainment, and we wanted a name that looks forward rather than one that simply splices together the past.That brought us to Skydance — a name that obviously has special meaning to David, who chose it for his own studio 20 years ago. It evokes possibility: scale and ambition, creativity and imagination, artistry and innovation. Most importantly, it doesn't compete with either legacy. It gives the new company an identity of its own while allowing Paramount and Warner Bros. — and all our extraordinary brands — to remain in the spotlight.Because ultimately, what we are bringing together is much more than brands and libraries. It is the creative spirit, ambition and craftsmanship that have kept these companies culturally relevant for generations. That spirit will continue to be a core part of who we are at Skydance.And who we are will also be defined by what we strive to accomplish — not just for our company, but for the industry at large. That means looking ahead to the forces that are reshaping entertainment and finding ways to harness them to expand what's possible — for creators, for audiences and for the business itself.Financial strengthWe're building a diversified company with the financial strength to compete aggressively and the discipline to create sustainable value. That's not just important to our investors — it's important to all of us. A financially strong, well-run company gives us the freedom to take creative risks, invest in our people and our technology, and pursue the kind of opportunities that set us apart.In concrete terms, we are together one of the largest media and entertainment companies in the world, with nearly $70 billion in revenue. As we have said publicly, we are also targeting at least $6 billion in synergies, which will make us leaner and more nimble and free up capital to invest in the stories, creators and technology that matter most.Integrating two companies will bring change, including difficult decisions that affect our workforce. We are committed to handling this process thoughtfully and respectfully.The road aheadToday is Day One.We have an incredible collection of assets. Extraordinary creative talent. Global scale. The technology to lead. And most important, we have the people who bring it all to life every day.We have everything we need to win, and that is our goal: to build a next-generation global media and entertainment company that puts audiences first, empowers creators, embraces innovation and creates lasting value for generations to come.But none of this happens without you. Thank you for everything you've brought to this moment. We're proud to write this next chapter with you.Now the real work begins.Let's go!David and Ynon

Read next

James Faris You're currently following this author! Click to unsubscribe from email alerts.

James Faris is a media correspondent in New York City.He covers the business of media & entertainment, specifically the streaming, TV, and AI strategies of Hollywood giants like Disney, Paramount, and Netflix. He previously wrote about the stock market, the economy, and real estate.James joined Business Insider after graduating magna cum laude from James Madison University.Email James at [email protected] and follow him on LinkedIn.

Media Exclusive Warner Bros. More

The expanded relationship builds on a series of agreements announced this year, strengthening Dentsply Sirona’s North American dealer network and giving more customers access to its products and technology.  | Source: DENTSPLY SIRONA Inc.

CHARLOTTE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona (Nasdaq: XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced an expanded relationship with Midwest Dental Equipment & Supply, an independent, family-owned distributor of dental supplies, equipment, and technology.

Effective November 1, 2026, Midwest Dental will begin offering Dentsply Sirona’s technology portfolio in the United States, building on a relationship that has historically focused on consumables. The expanded relationship increases access to Dentsply Sirona’s digital dentistry solutions through Midwest Dental’s network of sales, service, and technical specialists.

The agreement reflects continued execution against Dentsply Sirona’s commitment to broaden access to its connected technology portfolio by expanding relationships with trusted distribution partners across North America.

Together, these agreements support Dentsply Sirona’s commercial strategy to increase customer access, strengthen coverage in key markets and support adoption of the Company’s connected technology solutions.

Founded in 1988 and headquartered in Wichita Falls, Texas, Midwest Dental Equipment & Supply is the largest independent, family-owned distributor in the Southern U.S. serving dental professionals nationwide, with sales, service, and technical teams on the ground in Texas, Oklahoma, New Mexico, and Arkansas.

“Midwest Dental has built strong relationships across the markets it serves, from independent practices to larger customer groups, making it an important partner as we continue expanding access to connected dentistry,” said Mark Bezjak, Group Vice President, Americas RCO at Dentsply Sirona. “By bringing our technology portfolio to Midwest Dental’s customers, we are extending the reach of a connected ecosystem designed to help practices improve efficiency, simplify workflows and support long-term growth.”

“Our customers trust us to help them make the best technology decisions that are right for their practice,” said Matt LeVasseur, Chief Executive Officer at Midwest Dental Equipment & Supply. “Adding Dentsply Sirona’s technology portfolio allows us to offer the industry’s leading and most complete digital dentistry solutions. When you add support from local service technicians, in-depth training and technical expertise, we’re able to exceed our customers’ expectations. In today’s busy marketplace, it is important for our customers to have an easy, seamless and profitable solution for same-visit crown restorations and Dentsply Sirona’s technology allows Midwest Dental to do that at the highest level”

The Midwest Dental agreement marks Dentsply Sirona’s seventh North American dealer partnership enhancement of 2026, following new technology agreements with Benco Dental Supply Co., The Burkhart Dental Supply Co., Nashville Dental, Inc., The Atlanta Dental Supply Company, and Medline Sinclair, as well as a renewed partnership with Patterson Dental. Together, these agreements support Dentsply Sirona’s commercial strategy to expand customer access, strengthen coverage in key markets and accelerate adoption of the Company’s connected technology solutions.

About Dentsply Sirona

Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information Investors:

Wade Moody
Senior Manager, Investor Relations
[email protected]

Contact Information Press:

Marion Par-Weixlberger
Vice President, Public Relations, Corporate Communications & Brand
[email protected] 

Lakehouse Capital Pty Ltd raised its position in Workiva Inc. (NYSE:WK – Free Report) by 97.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 199,776 shares of the software maker’s stock after buying an additional 98,750 shares during the quarter. Workiva comprises about 10.6% of Lakehouse Capital Pty Ltd’s portfolio, making the stock its 3rd largest position. Lakehouse Capital Pty Ltd owned about 0.36% of Workiva worth $13,299,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Squarepoint Ops LLC increased its stake in Workiva by 110.7% in the second quarter. Squarepoint Ops LLC now owns 1,247,400 shares of the software maker’s stock valued at $60,511,000 after acquiring an additional 655,396 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Workiva by 88.5% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,109,646 shares of the software maker’s stock valued at $66,168,000 after purchasing an additional 520,839 shares during the last quarter. Hawk Ridge Capital Management LP acquired a new position in shares of Workiva during the 1st quarter worth $65,091,000. First Trust Advisors LP raised its holdings in shares of Workiva by 16.4% during the 1st quarter. First Trust Advisors LP now owns 862,936 shares of the software maker’s stock worth $51,457,000 after buying an additional 121,643 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Workiva during the 4th quarter worth $53,375,000. 92.21% of the stock is owned by institutional investors.

Insider Buying and Selling at Workiva In other news, EVP Brandon Ziegler sold 6,571 shares of the stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $75.97, for a total value of $499,198.87. Following the completion of the sale, the executive vice president owned 126,216 shares of the company’s stock, valued at approximately $9,588,629.52. This represents a 4.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.77% of the company’s stock.

Analysts Set New Price Targets WK has been the topic of a number of recent analyst reports. Zacks Research upgraded Workiva from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 11th. Citigroup reissued a “buy” rating on shares of Workiva in a report on Thursday, August 6th. Robert W. Baird raised their price target on shares of Workiva from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, September 16th. Wall Street Zen raised shares of Workiva from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 26th. Finally, Weiss Ratings upgraded shares of Workiva from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Workiva presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.00. Check Out Our Latest Analysis on Workiva

Workiva Trading Up 1.0% Workiva stock opened at $71.92 on Tuesday. The stock has a 50-day moving average price of $70.71 and a two-hundred day moving average price of $59.08. Workiva Inc. has a 12 month low of $43.34 and a 12 month high of $97.10. The company has a market capitalization of $4.04 billion, a PE ratio of 87.71 and a beta of 0.53.

Workiva (NYSE:WK – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The software maker reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.13. Workiva had a negative return on equity of 140.17% and a net margin of 4.87%.The company had revenue of $255.29 million during the quarter, compared to the consensus estimate of $251.16 million. During the same quarter in the prior year, the firm posted $0.19 earnings per share. The firm’s revenue was up 18.6% compared to the same quarter last year. Workiva has set its FY 2026 guidance at 3.380-3.390 EPS and its Q3 2026 guidance at 0.790-0.820 EPS. As a group, analysts predict that Workiva Inc. will post 1.31 earnings per share for the current fiscal year.

About Workiva (Free Report)

Workiva Inc is a cloud-based software company that helps organizations manage complex reporting, compliance and operational processes. Its platform connects data from multiple sources, enabling users to prepare, review and distribute financial reports, regulatory filings, management reports and other business documents through a collaborative digital environment.

The company’s products support financial reporting, environmental, social and governance (ESG) reporting, risk management, internal controls, audit management and regulatory compliance.

Recommended Stories Five stocks we like better than Workiva NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run A Manufacturing Surprise Could Be a Big Win for These 2 Companies What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks Want to see what other hedge funds are holding WK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Workiva Inc. (NYSE:WK – Free Report).

Receive News & Ratings for Workiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Workiva and related companies with MarketBeat.com's FREE daily email newsletter.

Global Net Lease's 9% yield is drawing income investors in, but a closer look at its cash flow numbers reveals a coverage ratio that keeps shrinking quarter by quarter, and a wall of debt maturities closing in fast.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Real estate investment trusts, or REITs, are extremely popular among income investors for their strong yields. But oftentimes, there’s more to the story than the payout.

Global Net Lease (NYSE:GNL) pays 76 cents per share each year. At a closing price of $8.14 on Oct. 5, that works out to a yield of about 9.34%. Income investors notice a number like that. A high yield only matters if the company can keep paying it, though, and Global Net Lease’s own cash flow numbers say the safety margin is getting thinner.

However, you have to judge it yourself: A dividend is unsustainable when the cash the business generates, its debt load and its refinancing schedule can’t comfortably pay for it, whatever the yield says.

Global Net Lease (GNL) Why the Yield Looks Tempting Global Net Lease is an equity REIT. It has buildings and collects rent from them. A mortgage REIT is a different animal: it lends money and earns the spread between its borrowing costs and its loan yields. That makes a mortgage REIT’s risk mostly about interest rates.

For Global Net Lease, the risks are tenants, lease rollover, property values, and refinancing. On the surface, the portfolio looks solid. Occupancy is 97% across 798 properties, 63% of tenants are investment grade or implied investment grade, and the weighted average remaining lease term is 5.7 years. Fitch and S&P both raised the company to investment-grade BBB- in 2025.

Why AFFO Is the Right Yardstick Measuring REIT dividends against earnings per share (EPS) gives a misleading picture. GAAP earnings subtract depreciation, which is a non-cash charge, along with impairments and losses on property sales. For a landlord, those charges can be large. Global Net Lease posted a GAAP net loss of $225.46 million in fiscal 2025, which would make any EPS payout ratio meaningless. Adjusted funds from operations (AFFO) adds back depreciation and subtracts recurring capital spending. That gets much closer to the cash actually available to pay shareholders, and it’s the measure that matters here.

Coverage Is Shrinking AFFO came in at $0.99 per share in 2025. Management’s 2026 guidance is 82 cents to 85 cents, even after raising it from 80 cents to 84 cents. Against the 76-cent dividend, that means an AFFO payout ratio of about 89% to 93%. The quarterly numbers point the same way.

AFFO per share was 24 cents in Q3 2025, then 22 cents in Q4, 21 cents in Q1 2026 and 22 cents in Q2 2026. Each of those quarters had to cover a $0.19 payout. In Q2, that meant about 86% of AFFO went out the door.

Revenue explains the slide. Asset sales since 2024 total about $3.4 billion, and fiscal 2025 revenue fell 38.47% to $495.29 million. Q2 2026 revenue of $112.47 million was down another 9.95% from a year earlier. The earnings base is getting smaller while the dividend remains the same.

Share Price Weakness Drives the Yield Global Net Lease’s dividend has shrunk over time. The company paid 53.25 cents a quarter in 2019, then cut to 40 cents, 35.4 cents, 27.5 cents and finally to 19 cents starting in April 2025. The yield is high because the stock trades at low levels. The stock is down 7.83% over five years and 9.84% over the past month, even though it’s up 10.63% over 12 months. The yield was 10.1% at the end of Q2 2025 and 8.5% at the end of Q2 2026. Since then, the recent drop in the stock has pushed it back up.

Debt Maturities Are the Pressure Point Leverage has come down. Net debt to adjusted EBITDA was 7.6x at the end of 2024 and is now 6.6x, against a target range of 6.5x to 6.9x. Even so, net debt still stands at $2.3 billion. The weighted average debt maturity has shortened to 2.7 years from 3.2 years. Short-term debt was $472.9 million on June 30, up from $94.5 million a quarter earlier, while current assets were just $156.1 million. Refinancing that debt at the current 4.1% weighted average rate keeps the math manageable. If rates on new debt come in higher, they eat straight into AFFO.

Leases add another layer of risk. About 8.5% of annualized straight-line rent expires in 2026 and 7.5% in 2027. Office properties, which make up 25% to 27% of the portfolio, are being sold into a weak market. Buybacks are also competing for cash: the company has spent $169.7 million buying back 20.9 million shares.

What Has to Go Right Management is counting on an industrial portfolio acquisition that it expects to be about 4% accretive to AFFO per share without adding leverage. The deal would raise industrial exposure to around 50% of straight-line rent. Office sales also need to close at decent prices. CEO Michael Weil said on the August earnings call, “By no means do we want a fire sale.” Liquidity of about $919 million buys the company time.

The test worth watching is quarterly AFFO per share compared with the $0.19 dividend. If full-year 2026 AFFO comes in below the 82-cent low end of guidance, or if a quarterly figure slips toward $0.19, the buffer is gone. If the acquisition raises quarterly AFFO back toward the levels of late 2025, the warning weakens. A near-double-digit yield coupled with a shrinking coverage ratio is one of the classic patterns we flagged in a free guide to dividend trap warning signs.

Yield Alone Is Never the Thesis When a dividend gets cut, the stock usually falls with it. Global Net Lease shareholders have been through that more than once. Right now the dividend is covered, but the buffer is getting smaller while debt maturities come closer. For income investors considering the yield, the AFFO line in the next earnings report is the number to keep an eye on.

Contact [email protected] for any questions or corrections.

Energy Transfer (ET -0.12%) is one of the largest U.S.-listed master limited partnerships (MLPs) specializing in the ownership of pipelines and other midstream energy assets. Based on current prices, Energy Transfer has a forward distribution yield of 6.64%.

In other words, add up its quarterly cash distributions and divide by the current stock price, and you'll get approximately this figure. Considering this, let's run the numbers and see how many shares of this pipeline stock you'd need to own in order to earn $250 monthly.

Image source: Getty Images.

Building a $250-per-month income stream from Energy Transfer stock Considering the complexities of MLPs and taxation, we will focus on a gross dividend income of $250 per month from an Energy Transfer position, for purposes of our calculation. A monthly payout of $250 comes out to $3,000 per year. Energy Transfer pays $1.36 per share in annual distributions.

Today's Change

(

-0.12

%) $

-0.03

Current Price

$

20.70

Divide $3,000 by $1.36, and you get 2,205 shares, worth around $45,136 based on Energy Transfer's current stock price. From this position, you'd generate around $2,998.80 in dividend income annually, or just under $250 per month.

The case for reinvesting your distributions If you have just over $45,000, buying Energy Transfer is a great way to get an upper-single-digit forward yield from your investment. Besides the relatively high forward distribution rate, this MLP has a long track record of steadily raising its payout by several percentage points each year, which helps ensure your investment keeps up with inflation.

However, what if, instead of spending your Energy Transfer distributions or investing them elsewhere, you chose to reinvest cash distributions into more MLP units? Over the past five years, Energy Transfer has generated total returns, or price appreciation plus distributions, totaling 204% (24.9% annually), versus just 93% (14% annually) for the S&P 500 (^GSPC +0.47%) . Although total returns can vary over time, this figure alone demonstrates the compounding potential of this stock.

Alcoa Corporation (NYSE:AA) will release earnings for its third quarter after the closing bell on Thursday, Oct. 15.

Analysts expect the Pittsburgh, Pennsylvania-based company to report quarterly earnings of $1.47 per share, versus a loss of 2 cents per share in the year-ago period. The consensus estimate for AA’s quarterly revenue is $3.75 billion. It reported $3 billion last year, according to Benzinga Pro.

On July 16, Alcoa reported mixed second-quarter financial results.

Alcoa shares rose 3.7% to close at $43.49 on Monday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Freedom Broker analyst Vitaly Kononov maintained a Buy rating and increased the price target from $64 to $76 on Sept. 22, 2026. This analyst has an accuracy rate of 72%. Wells Fargo analyst Timna Tanners maintained an Overweight rating and cut the price target from $71 to $60 on Sept. 18, 2026. This analyst has an accuracy rate of 64%. Argus Research analyst Alexandra Yates maintained the stock with a Buy rating and slashed the price target from $73 to $55 on July 22, 2026. This analyst has an accuracy rate of 59%. BMO Capital analyst Katja Jancic maintained a Market Perform rating and cut the price target from $60 to $55 on July 17, 2026. This analyst has an accuracy rate of 74%. JP Morgan analyst Bill Peterson maintained the stock with a Neutral rating and cut the price target from $55 to $52 on July 17, 2026. This analyst has an accuracy rate of 60%. Considering buying AA stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

COLUMBIA, Md., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Tenable® Holdings, Inc. (NASDAQ: TENB), the exposure management company, today announced the appointment of Charlie Bell to its Board of Directors. A seasoned technology executive with nearly four decades of hands-on software engineering and operational leadership, Bell brings deep expertise in building and scaling complex cloud systems to Tenable’s board as the company continues to advance its AI-powered exposure management platform.

Bell’s appointment comes at a crucial inflection point for the enterprise cybersecurity industry. As organizations navigate the convergence of AI integration, cloud infrastructure and an accelerating volume of software vulnerabilities, Bell’s engineering-first perspective and extensive background in cloud-scale product architecture will reinforce Tenable’s strategic direction.

“Charlie Bell is one of the foundational architects of modern cloud computing and enterprise security,” said Mark Thurmond, Co-CEO of Tenable. “His track record of engineering resilient, large-scale software platforms and leading world-class product teams is phenomenal for our business.”

"Charlie brings deep experience leading organizations through major technology shifts, from the rise of cloud computing at massive scale to the security transformations that followed. He'll bring that same judgment to Tenable as we lead the security market into this next era of AI-driven exposure management and proactive risk reduction," said Steve Vintz, Co-CEO of Tenable.

Bell spent over two decades at Amazon Web Services (AWS), playing a central role in building its cloud infrastructure from its inception into a global, multi-billion dollar business. As a Senior Vice President at AWS, he led core engineering, utility computing and operational teams responsible for scaling cloud platforms used by millions of enterprises worldwide. Most recently, Bell served as Executive Vice President of Security, Compliance, Identity and Management at Microsoft, where he oversaw the company's enterprise security strategy, product engineering and threat intelligence operations.

"Tenable has established itself as the pioneer in exposure management, helping organizations focus on the risks that actually matter before they’re exploited," said Bell. "Throughout my career, I’ve been driven by a conviction that great engineering is the foundation of effective security. Tenable’s vision, backed by its massive data lake and advanced exposure intelligence, positions it uniquely to address the complexities of today’s AI attack surface. I look forward to working alongside the executive leadership team and the board to help guide the company's next phase of engineering-driven growth."

With Bell's appointment, Tenable strengthens its board's technical depth, ensuring the company remains positioned to help global organizations reduce risk across AI, cloud, identity, OT and traditional IT environments.

About Tenable
Tenable® is the exposure management company, exposing and closing the cybersecurity gaps that erode business value, reputation and trust. The company’s AI-powered exposure management platform radically unifies security visibility, insight and action across the attack surface, equipping modern organizations to protect against attacks from IT infrastructure to cloud environments to critical infrastructure and everywhere in between. By protecting enterprises from security exposure, Tenable reduces business risk for over 40,000 customers around the globe. Learn more at tenable.com.

Media Contact:
Tenable PR
[email protected]

Forward-Looking Statements
This press release contains “forward-looking” statements, as that term is defined under the federal securities laws, including statements regarding the impact of the appointment of Charlie Bell to Tenable’s Board of Directors, anticipated strategic benefits and contributions to Tenable’s product development, platform engineering and AI-powered exposure management leadership, and future growth. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Tenable’s control. Tenable’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including risks and uncertainties related to the development, integration and performance of advanced AI technologies, market acceptance of Tenable’s exposure management platform, and other risks detailed in Tenable’s Form 10-K filed with the Securities and Exchange Commission (“SEC”) for the year ended December 31, 2025, in Tenable’s quarterly reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026 and in other filings and reports that Tenable may file from time to time with the SEC. The forward-looking statements included in this press release represent Tenable’s views as of the date of this press release. Tenable anticipates that subsequent events and developments will cause Tenable’s views to change. Tenable undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tenable’s views as of any date subsequent to the date of this press release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/55656433-2430-4ed9-9bc9-f409ee671bdc

Charlie Bell Appointed to Tenable Board of Directors Charlie Bell was appointed to the Board of Directors of Tenable in October 2026

Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression
CONSHOHOCKEN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the publication of a pre-specified secondary analysis from the Phase 3 MAESTRO-NASH trial in the Journal of Hepatology evaluating whether common genetic risk variants associated with MASH altered patient response to Rezdiffra® (resmetirom).

The analysis demonstrated that treatment with Rezdiffra resulted in fibrosis improvement, MASH resolution and liver fat and biomarker reductions across patients with several well-established genetic variants associated with MASH progression, including PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7. The findings suggest that Rezdiffra may have a therapeutic effect regardless of genetic risk factors that contribute to more severe disease.

“Understanding how common MASH risk alleles may influence a patient’s response to treatment will be increasingly important as the treatment landscape and number of diagnosed patients continue to evolve. For example, there is emerging evidence suggesting that response to various therapies could differ in individuals with MASH carrying the PNPLA3 allele, and it will be important to perform similar analyses for other approved and investigational MASH therapies moving forward,” said Naga Chalasani, M.D., David W. Crabb Professor of Gastroenterology and Hepatology at Indiana University School of Medicine and lead author of the study. “It is encouraging to see that Rezdiffra demonstrated consistent effects on liver histology and biomarkers across the genetic risk subgroups evaluated, supporting broad applicability across patients with this serious liver disease.”

“MASH is a complex, heterogeneous disease driven by both metabolic and genetic factors,” said David Soergel, M.D., Chief Medical Officer of Madrigal. “These data reinforce that Rezdiffra provides broad benefit across patients with MASH, including those with the most common genetic risk variants that may put them at higher risk of disease progression, cirrhosis and liver cancer, strengthening its position as a foundation of MASH treatment. These results also support our pipeline strategy of developing precision approaches targeting well-defined genetic drivers of disease that may complement Rezdiffra in specific patient populations.”

About the Analysis
The publication, “Effects of select MASH risk genotypes on resmetirom efficacy on liver histology and biomarkers in patients with MASH and liver fibrosis: a secondary analysis of the MAESTRO-NASH trial,” reports results from a pre-specified secondary analysis of 738 patients from the Phase 3 MAESTRO-NASH trial who consented to genetic testing and completed baseline and Week 52 liver biopsies. The analysis was not prospectively powered to detect small genotype-by-treatment interactions, and only select common variants were assessed. Across all major efficacy endpoints, including MASH resolution, fibrosis improvement, MRI-PDFF reduction and multiple biomarkers, there was no meaningful difference in treatment response based on MASH genetic risk variants or a composite genetic risk score.

Among the findings:

Resmetirom responses were consistent across PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7 risk groups for MASH resolution, fibrosis improvement and MRI-PDFF reduction.The treatment effect remained consistent after accounting for sex and Hispanic ethnicity.Results suggested Rezdiffra's mechanism of action as a thyroid hormone receptor-beta (THR-β) agonist is not affected by common genetic pathways associated with MASH progression and severity.Patients with high-risk genotypes of PNPLA3 or HSD17B13 demonstrated reduced frequency of metabolic risk factors, including diabetes and hypertension, suggesting patients with greater genetic risk could still have high stages of fibrosis, even if they had fewer traditional metabolic risk factors.Because this was a secondary analysis with limited numbers in some genotype groups, smaller genotype-specific effects or rarer variants cannot be excluded.In the overall MAESTRO-NASH trial (n=966), Rezdiffra was generally well tolerated, with the frequency of serious adverse events similar across treatment groups. See additional risk information below. Madrigal's R&D strategy includes developing therapies that target validated disease mechanisms and may complement Rezdiffra’s broad therapeutic effects, especially in patient populations with specific needs. In May 2026, the company announced the addition of MGL-0795 (formerly ARO-PNPLA3), a clinical-stage, small interfering RNA (siRNA) asset targeting PNPLA3 to its pipeline as a potential precision-medicine approach. Mutations in the PNPLA3 gene are strongly associated with MASH progression and a high risk of developing hepatocellular carcinoma (HCC). Madrigal will consult with the FDA on design of a Phase 2 combination trial with Rezdiffra.

In this analysis, MASH resolution in the PNPLA3 subgroup was achieved in 38.4%, 30.8% and 30.5% of Rezdiffra-treated patients, versus 12.9%, 5.1% and 11.7% in patients in the placebo group across low, intermediate and high-risk genotypes, respectively, while fibrosis improvement was 34.2%, 29.5% and 31.4% versus 14.1%, 13.7% and 15.0%, respectively.

About MASH
Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, the need for liver transplantation and premature mortality. MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation in the U.S., and the fastest-growing indication for liver transplantation in Europe.

Once patients progress to MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically: these patients have a 10 to 17 times higher risk of liver-related mortality as compared to patients without fibrosis.

Patients with MASH who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an independent driver of cardiovascular disease, the leading cause of mortality for patients.

As disease awareness improves and disease prevalence increases, the number of patients diagnosed with F2 to F4c MASH is growing.

About Rezdiffra
What is Rezdiffra?
Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.

Before you take Rezdiffra, tell your healthcare provider about all of your medical conditions, including if you:

have any liver problems other than MASH.have gallbladder problems or have been told you have gallbladder problems, including gallstones.are pregnant or plan to become pregnant. It is not known if Rezdiffra will harm your unborn baby. A pregnancy safety study for women who take Rezdiffra during pregnancy collects information about the health of you and your baby. You or your healthcare provider can report your pregnancy by visiting https://pregnancyregistry.madrigalpharma.com/ or calling 1-800-905-0324. are breastfeeding or plan to breastfeed. It is not known if Rezdiffra passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Rezdiffra.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

Rezdiffra and other medicines may affect each other, causing side effects. Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works.Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides, because Rezdiffra is not recommended in patients taking these medicines.Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines to help lower your cholesterol.Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. What are the possible side effects of Rezdiffra?
Rezdiffra may cause serious side effects, including:

liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice) or stomach pain/tenderness.gallbladder problems. Gallbladder problems such as gallstones, or inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with MASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.The most common side effects of Rezdiffra include: diarrhea, nausea, itching, stomach pain, vomiting, dizziness and constipation.
These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal at 1-800-905-0324.

Please see the full Prescribing Information, including Patient Information, for Rezdiffra.

About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com and follow us on LinkedIn.

Forward-Looking Statements
This press release includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements related to the therapeutic effect of Rezdiffra across genetic variants associated with MASH, Madrigal’s ability to develop its pipeline and the potential benefit of Madrigal’s pipeline candidates for the treatment of MASH. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; our ability to successfully commercialize Rezdiffra in the U.S. and Europe; risks related to obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; our history of operating losses and the possibility that we may never achieve or maintain profitability; risks associated with meeting the objectives of our clinical trials, including, but not limited to our ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for our trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action or of any other product candidate; market demand for and acceptance of Rezdiffra; our ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitors; future topline data timing or results; our ability to prevent and/or mitigate cyber-attacks; our ability to protect our intellectual property rights; the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to our business and our ability to comply with such laws and regulations. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s submissions filed with the U.S. Securities and Exchange Commission (SEC) for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2025, and as updated from time to time by Madrigal’s other filings with the SEC.

Madrigal may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Madrigal’s website in addition to following its press releases, filings with the SEC, public conference calls, and webcasts.

Madrigal Pharmaceuticals, Rezdiffra® and associated logos are trademarks of Madrigal Pharmaceuticals, Inc.

Investor Contact
Tina Ventura, [email protected]

Media Contact
Krysta Pellegrino, [email protected]

Maximus, Inc. (NYSE:MMS – Get Free Report) declared a quarterly dividend on Monday, October 5th. Investors of record on Friday, November 13th will be paid a dividend of $0.33 per share by the health services provider on Monday, November 30th. This represents a $1.32 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Friday, November 13th.

Maximus has increased its dividend by an average of 0.0%annually over the last three years and has raised its dividend annually for the last 2 consecutive years. Maximus has a payout ratio of 19.8% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Maximus to earn $8.36 per share next year, which means the company should continue to be able to cover its $1.32 annual dividend with an expected future payout ratio of 15.8%.

Maximus Trading Up 3.4% Shares of Maximus stock opened at $54.41 on Tuesday. Maximus has a fifty-two week low of $51.04 and a fifty-two week high of $100.00. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.42 and a current ratio of 2.42. The company has a market capitalization of $2.85 billion, a P/E ratio of 8.04 and a beta of 0.59. The company has a fifty day moving average of $57.18 and a 200 day moving average of $60.09.

Maximus (NYSE:MMS – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The health services provider reported $2.22 EPS for the quarter, beating the consensus estimate of $2.21 by $0.01. The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.33 billion. Maximus had a return on equity of 24.91% and a net margin of 7.07%.The business’s revenue was down 5.1% on a year-over-year basis. During the same period in the previous year, the business earned $2.16 earnings per share. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. On average, sell-side analysts anticipate that Maximus will post 8.03 earnings per share for the current fiscal year. Wall Street Analyst Weigh In Several research analysts have weighed in on MMS shares. Wall Street Zen downgraded Maximus from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Maximus in a research report on Monday, August 17th. Finally, Zacks Research raised shares of Maximus from a “strong sell” rating to a “hold” rating in a report on Thursday, October 1st. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company currently has an average rating of “Hold”.

Get Our Latest Stock Report on MMS

About Maximus (Get Free Report)

Maximus, Inc (NYSE:MMS) is a provider of government services and technology-enabled solutions. The company partners with federal, state, provincial and local governments to administer public programs, improve service delivery and support interactions between governments and the people they serve.

Its business activities include health and human services administration, employment and workforce services, child support and eligibility services, customer contact centers, program management, consulting and digital transformation.

See Also Five stocks we like better than Maximus NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run A Manufacturing Surprise Could Be a Big Win for These 2 Companies What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks

Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.

Integration streamlines investor onboarding to private funds, digitalizes fund subscriptions, and centralizes investment reporting for institutional investors wealth managers

, /PRNewswire/ -- SUBSCRIBE, the global fintech company providing the leading enterprise operating system for alternative investments, today announced a strategic partnership with FactSet (NYSE: FDS| NASDAQ: FDS), a leading global data and AI solutions provider to the financial markets. The partnership integrates SUBSCRIBE's private markets workflow and data solution into FactSet's leading platform for trusted data, research, & analytics, and advisor and client intelligence, delivering an end-to-end private markets experience for institutional investors and wealth managers.

The integration provides FactSet's clients with seamless investor onboarding to private funds, digitalized fund subscriptions, and centralized post-trade investment reporting, enabling investors to manage, analyze, and monitor private and public investments side by side within a single platform.

"Our goal has always been to rebuild the critical infrastructure and data layers required for managing private market fund investments," said Rafay Farooqui, Founder and CEO of SUBSCRIBE. "FactSet is one of the investment and wealth management industries' leading providers of portfolio performance, risk analytics, and reporting software. Together, we can deliver a truly superior end-to-end experience to institutional and wealth management investors at scale."

"This partnership creates meaningful value for our clients, streamlining and synthesizing data for greater visibility into private market portfolios," said Greg King, Senior Director and Head of Wealth Management at FactSet. "As inflows to alternative investments continue to grow, our integrated offering with SUBSCRIBE is uniquely positioned to deliver value across the total portfolio, including both public and private investments."

SUBSCRIBE currently serves both institutional investment and wealth management firms, supporting over $6 trillion in private market assets for leading institutional investors and alternative asset managers, and more than 55,000 financial advisors across 1200 wealth management firms. The partnership extends SUBSCRIBE's reach to FactSet's more than 8,600 global clients and 219,000 individual users, equipping them with alternative investment workflow tools embedded directly into their existing research, analytics, and investment processes.

For more information, visit www.subscribeplatform.com or www.factset.com.

About SUBSCRIBE
SUBSCRIBE is a fintech company digitally transforming the landscape of alternative investments for alternative asset managers, institutional investors, wealth managers, law firms, and fund administrators. Our platform technology modernizes the archaic infrastructure of private fund investments by delivering a central operating system — catering to every role within the investment process empowering them to connect any fund, any investor, anywhere in the world on a single platform. SUBSCRIBE supports over $6 trillion in private market assets and is the trusted technology partner to thousands of firms that rely on our end-to-end enterprise solution to scale their private market investment programs and manage investment processes across pre-trade, trade, and post-trade fund workflows. For additional information, visit www.subscribeplatform.com or follow the company on LinkedIn.

Media Contact:
[email protected]

SOURCE SUBSCRIBE

, /PRNewswire/ -- Canadian Solar Inc. (the "Company" or "Canadian Solar") (NASDAQ: CSIQ) today announced that e‑STORAGE, its energy storage solutions business, has signed an agreement to supply and commission a 100 MW/200 MWh battery energy storage system (BESS) for OX2's Muswellbrook Solar Farm and Battery, a solar-plus-storage project in New South Wales, Australia. Shipments are scheduled to begin in Q3 2027, with commercial operation targeted for Q3 2028. The battery cells and SolBank system will be produced in-house at Canadian Solar's manufacturing facilities, giving the customer end-to-end supply chain visibility and ensuring strict quality control across the product.

e‑STORAGE will deliver an integrated solution built on SolBank 3.0 battery containers, paired with Power Conversion Systems (PCS), plant controls, and the Company's proprietary EQ-S Energy Management System (EMS) developed and built in-house by e‑STORAGE's North American software team. e‑STORAGE will be responsible for the R1 grid connection studies, supply the hybrid power plant controller that coordinates the battery with the co-located solar farm, and lead the overall integration and commissioning of the hybrid project. The arrangement is backed by a 20-year long-term service agreement (LTSA), placing hardware, proprietary software, and long-term performance under a single accountable partner.

The project sits roughly 2.5 kilometers east of Muswellbrook, on land at a former coal mine within the Hunter-Central Coast Renewable Energy Zone. The location is significant: as the region's aging coal generators wind down toward retirement in the early 2030s, the dispatchable capacity they once provided must be replaced. Two-hour storage fills that gap directly, holding midday solar output and releasing it into the evening demand peak when supply from retiring thermal plants tightens.

Once operational, the system will support the long-term hybrid power purchase agreement OX2 has signed for the project, converting variable solar output into firm, contracted supply. By storing and dispatching solar energy on demand, the BESS strengthens grid reliability in a region transitioning away from coal and helps deliver firm renewable power to the communities in the Hunter Region.

Steve Symons, Vice President, OX2 Australia, said: "This battery storage system is what turns Muswellbrook into a true hybrid facility — pairing solar generation with storage so we can capture energy when the sun is shining and deliver it when the grid needs it most. It's a key step in providing firm, reliable renewable power to the Hunter region."

Jeff Roy, President of e‑STORAGE, said:  "Australia's energy transition is being decided in regions like the Hunter, where storage now has to carry the load that retiring coal once did. We control this project from the cell through to our own energy management software and 20 years of service, which means OX2 has one partner accountable for how the system performs over its full life."

About Canadian Solar Inc.

Canadian Solar is one of the world's largest solar technology and renewable energy companies. Founded in 2001 and headquartered in Kitchener, Ontario, the Company is a leading manufacturer of solar photovoltaic modules; provider of solar energy and battery energy storage solutions; and developer, owner, and operator of utility-scale solar power and battery energy storage projects. Over the past 25 years, Canadian Solar has successfully delivered nearly 180 GW of premium-quality solar photovoltaic modules to customers across the world. Through its energy storage solutions business e-STORAGE, Canadian Solar has shipped over 23 GWh of battery energy storage solutions to global markets and had a contracted backlog of $3.5 billion as of June 30, 2026. Since entering the project development business in 2010, Canadian Solar has developed, built, and connected approximately 12.4 GWp of solar power projects and 6.4 GWh of battery energy storage projects globally. Its geographically diversified project development pipeline includes approximately 22 GWp of solar and 84 GWh of battery energy storage capacity in various stages of development. Canadian Solar is one of the most bankable companies in the solar and renewable energy industry, having been publicly listed on the NASDAQ since 2006. For additional information about the Company, follow Canadian Solar on LinkedIn or visit www.canadiansolar.com.

About e-STORAGE

e-STORAGE is a subsidiary of Canadian Solar and a leading company specializing in designing, manufacturing, and integrating battery energy storage systems for utility-scale applications. e-STORAGE offers proprietary battery energy storage systems (BESS) spanning battery cells, battery PACKs, power conversion systems (PCS), energy management systems (EMS) and system integration. It also provides comprehensive EPC services and full-lifecycle station operation and asset management, helping customers improve grid operations across the project lifecycle. For more info, please refer to the Media&PR section of www.csestorage.com and follow our LinkedIn page.

Safe Harbor/Forward-Looking Statements

Certain statements in this press release, including those regarding the Company's expected future shipment volumes, revenues, gross margins, and project sales are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially. These statements are made under the "Safe Harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by such terms as "may", "will", "expect", "anticipate", "future", "ongoing", "continue", "intend", "plan", "potential", "prospect", "guidance", "believe", "estimate", "is/are likely to" or similar expressions, the negative of these terms, or other comparable terminology. These forward-looking statements include, among other things, our expectations regarding global electricity demand and the adoption of solar and battery energy storage technologies; our growth strategies, future business performance, and financial condition; our transition to a long-term owner and operator of clean energy assets and expansion of project pipelines; our ability to monetize project portfolios, manage supply chain fluctuations, and respond to economic factors such as inflation and interest rates; our outlook on government incentives, trade measures, regulatory developments, and geopolitical risks; our expectations for project timelines, costs, and returns; competitive dynamics in solar and storage markets; our ability to execute supply chain, manufacturing, and operational initiatives; access to capital, debt obligations, and covenant compliance; relationships with key suppliers and customers; technological advancement and product quality; and risks related to intellectual property, litigation, and compliance with environmental and sustainability regulations. Other risks were described in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 20-F filed on April 10, 2026. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, level of activity, performance, or achievements. Investors should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today's date, unless otherwise stated, and Canadian Solar undertakes no duty to update such information, except as required under applicable law.

Canadian Solar Inc. Investor Relations Contact

Wina Huang
Investor Relations
Canadian Solar Inc.
[email protected]

e-STORAGE MEDIA CONTACT
[email protected] 

SOURCE Canadian Solar Inc.

August orders increase 16.4%, while estimated backlog grows 145.1% to approximately $898,000. Preliminary net sales reach $2.34 million, extending the Company's eight-month sales climb

WEST SENECA, NY / ACCESS Newswire / October 6, 2026 / Worksport Ltd. (Nasdaq:WKSP) ("Worksport" or the "Company"), a U.S.-based innovator and manufacturer of hybrid and clean energy solutions primarily for the light truck, overlanding, and global consumer goods markets, today announced preliminary August 2026 sales orders of approximately $2.92 million, an increase of 16.4% from July 2026, representing an annualized sales-order run rate of $35.05 million. Preliminary net sales increased 5.6% to $2.34 million, while estimated month-end backlog rose to approximately $898,000, reflecting order intake that exceeded invoicing during August.

Monthly Net Sales Extend Eight-Month Climb

Worksport's preliminary monthly net sales increased from approximately $937,000 in January to $2.34 million in August, representing growth of approximately 150%. Each successive month exceeded the previous month across the January-to-August period, with monthly growth averaging approximately 14.6% across 2026.

Orders Outpace Invoicing; Estimated Backlog Increases 145.1%

August sales orders increased 16.4% from approximately $2.51 million in July to approximately $2.92 million, while invoiced sales increased 5.6% from approximately $2.27 million in July to approximately $2.39 million. August orders exceeded invoicing by approximately $532,000, increasing Worksport's estimated backlog from an updated July balance of approximately $366,000 to $898,000, a 145.1% increase.

Annualized Sales-Order Run Rate Increases to $35.05 Million

Based on August sales orders, Worksport's annualized sales-order run rate increased to approximately $35.05 million, compared with approximately $30.13 million using the updated July order figure. This represents an increase of approximately $4.93 million, or 16.4%.

August marked the fourth consecutive month with preliminary gross margin above 30%, as higher sales generated additional gross profit alongside margin expansion.

CEO Commentary

"Our approximately $35 million annualized sales-order run rate reflects growing demand and a meaningful opportunity to move Worksport toward positive operating cash flow," said Steven Rossi, Founder and Chief Executive Officer of Worksport. "We have now maintained preliminary gross margin above 30% for four consecutive months. If we sustain that margin strength while growing revenue, we can generate more gross profit to cover operating expenses and narrow the gap to positive operating cash flow. Higher production volumes should also help us spread fixed manufacturing costs across more units, supporting further margin improvement as we scale. Our priority is to convert this higher order pace into shipments and cash while keeping spending disciplined, so revenue growth translates into a financially stronger business for shareholders."

Stay tuned for more information and join our mailing list to stay up to date with the latest: Join Worksport's Newsletter

Contacts

Investor Relations, Worksport Ltd. T: 1 (888) 554-8789-128

W: investors.worksport.com W: www.worksport.com E: [email protected]

Connect with Worksport Chief Executive Officer, Steven Rossi

Steven Rossi LinkedIn | Note: CEO Steven Rossi has terminated the use of X (formerly Twitter)

About Worksport

Worksport Ltd. (Nasdaq:WKSP), through its subsidiaries, designs, develops, manufactures, and owns the intellectual property on a variety of tonneau covers, solar integrations, portable power systems, and clean heating & cooling solutions. Worksport has an active partnership with Hyundai for the SOLIS Solar cover. Additionally, Worksport's hard-folding cover, designed and manufactured in-house, is compatible with all major truck models and is gaining traction with newer truck makers including the electric vehicle (EV) sector. Worksport seeks to capitalize on the growing shift of consumer mindsets towards clean energy integrations with its proprietary solar solutions, mobile energy storage systems (ESS), and Cold-Climate Heat Pump (CCHP) technology. Terravis Energy's website is terravisenergy.com.

Connect with Worksport

Please follow the Company's social media accounts on X (previously Twitter), Facebook, LinkedIn, YouTube, and Instagram, the links of which are links to external third-party websites, as well as sign up for the Company's newsletters at investors.worksport.com.

Social Media Disclaimer

The Company does not endorse, ensure the accuracy of, or accept any responsibility for any content on these third-party websites other than content published by the Company. Investors and others should note that the Company announces material financial information to its investors using its investor relations website, press releases, Securities and Exchange Commission ("SEC") filings, and public conference calls and webcasts. The Company also uses social media to announce Company news and other information. The Company encourages investors, the media, and others to review the information the Company publishes on social media. The Company does not selectively disclose material non-public information on social media. If there is any significant financial information, the Company will release it broadly to the public through a press release or SEC filing prior to publishing it on social media.

Supplemental Operating Metrics and Preliminary Results

The Company presents sales orders, invoiced sales, estimated backlog and annualized run rates to provide additional context on demand and operating trends alongside its U.S. GAAP financial results. Management uses sales orders, invoiced sales, backlog and annual run rates to evaluate operating performance and support strategic decisions. These metrics are not substitutes for recognized net sales and may differ from similarly titled metrics used by other companies.

Sales orders represent the value of orders received and recorded during the applicable month. Invoiced sales reflect monthly invoicing before applying certain discounts. Estimated backlog is derived from sales orders and invoicing totals using a first-in, first-out allocation assumption, rather than an order-level analysis of fulfillment dates. These metrics are distinct from recognized net sales; conversion of sales orders and estimated backlog to revenue depend on fulfillment and satisfaction of applicable revenue-recognition requirements.

Annualized run rates multiply the applicable month's sales orders or preliminary net sales by twelve. The annualized run rates for sales orders calculation includes all sales orders received during that month, some of which may be in backlog. These calculations assume a constant monthly pace and are illustrative. The calculations do not reflect annual recurring revenue, a committed 12-month order book, full-year revenue guidance, or forecasts of future performance.

The monthly financial information in this release is preliminary and unaudited, remains subject to accounting close and review procedures, and may differ from final reported results.

Forward-Looking Statements

The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. Forward-looking statements in this release include expectations regarding order conversion, production volumes, gross margin improvement and progress toward positive operating cash flow. When used in this press release, the words "anticipate," "believe," "estimate," "scheduled," "expect," "future," "intend," "plan," "project," "envisioned," "should," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. These statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial situation may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) supply chain delays; (ii) acceptance of our products by consumers; (iii) delays in or nonacceptance by third parties to sell our products; (iv) competition from other producers of similar products; and (v) order cancellations or fulfillment delays, production constraints and working-capital requirements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the SEC, including, without limitation, our latest Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. The forward-looking statements made in this press release are made only as of the date of this press release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances, except as required by applicable law.

SOURCE: Worksport Ltd.

Comprehensive power modes, enhanced stamina metrics, a ComfortFit Fabric Band and Garmin Epic help endurance athletes and multiday adventurers train, race and explore even farther

, /PRNewswire/ -- Garmin (NYSE: GRMN) today announced Enduro™ 4, its longest-lasting GPS smartwatch with solar charging, which includes dynamic features and capabilities to take endurance enthusiasts farther on their next expedition. Utilizing an energy-efficient 1.4" MIP display in combination with a solar lens, Enduro 4 has up to 320 hours of battery life in activity mode1 or up to 90 days of battery life in smartwatch mode2. It also leverages innovative updates like grade-adjusted pace-based workout targets, grade-adjusted rolling pace, stamina zones, stamina curve and Garmin Epic multiday activity logging.

Comprehensive power modes, enhanced stamina metrics, a ComfortFit Fabric Band and Garmin Epic help endurance athletes and multiday adventurers train, race and explore even farther. "As interest and participation in ultra-endurance activities continue to grow, Enduro 4 is designed for athletes and adventurers who want gear they can trust to perform through every mile, every climb and every challenge. Intuitive features like comprehensive power modes make the most of the long-lasting battery life, while grade-adjusted metrics add a new dimension to preparing for hilly or mountainous terrain."
—Susan Lyman, Garmin Vice President of Consumer Sales and Marketing

Grade-adjusted features, stamina metrics and more

In addition to 100+ activity profiles, Enduro 4 introduces new capabilities to the Enduro line, optimized for trail runners, multiday hikers and backpackers, and endurance athletes.

Comprehensive power modes provide preset options to optimize battery life and performance based on the needs of the user. Configurations include Max Accuracy, which offers full-feature tracking for shorter efforts, and Max Battery, ideal for extended activity recording (up to 320 hours with solar charging). Grade-adjusted pace-based workout targets help athletes maintain the right effort range on hilly terrain, while grade-adjusted rolling pace provides a real-time view of pace over varying terrain. Stamina zones show athletes how their stamina impacts an activity, and stamina curve helps users understand how their endurance changes over time based on fitness and training history. With 50% more RAM than Enduro 3 and a more powerful, updated map engine, navigation is easier than ever with 30% faster panning and a smoother, more intuitive map interface for built-in routable maps. Perspective view provides more detail, both close-up and further away, allowing users to better anticipate what comes next. Garmin Epic allows athletes to combine multiple activities into one cohesive story in Garmin Connect™. Activities can be grouped together over days, weeks or months to create an "Epic", which enables users to add photos and share with family and friends, as well as see health and performance data aggregated during that period. Enhanced rowing tools provide additional training insights like VO2 max and power curve for indoor rowing activities, while expanded rucking features let users adjust pack weight during an activity and set target metrics like calories burned. Premium design for maximum versatility

Enduro 4 weighs in at an incredible 66 grams, making it one of the lightest ultraperformance smartwatches on the market. With a 51mm case, Power Sapphire™ scratch-resistant lens, titanium bezel and lightweight fiber-reinforced polymer case, it is built for the demands of the longest races and most taxing adventures, remaining remarkably light on the wrist. An integrated LED flashlight includes both white and red-light options, while a 10 ATM water resistance rating enables confident use in challenging environments.

New to Enduro 4, the ComfortFit Fabric Band combines exceptional comfort, durability and moisture-wicking performance with QuickFit™ functionality, making adjustments and swapping bands even simpler. 64 GB of memory gives users more room for onboard maps, music and data, making it easier to stay prepared for extended adventures away from home.

Available now, Enduro 4 has a suggested retail price of $899.99. Learn more at Garmin.com. 

Engineered on the inside for life on the outside, Garmin products have revolutionized life for adventurers, athletes, off-road explorers, road warriors and outdoor enthusiasts everywhere. Committed to developing products that enhance experiences, enrich lives and help provide peace of mind, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. Visit the Garmin Newsroom, email our media team, connect with @garminoutdoor on social, or follow our blog.  

1 Assumes continuous use for entire period in 50,000 lux conditions and typical use with activity mode (extended battery) selected
2 Assumes all-day wear with 3 hours per day outside in 50,000 lux conditions

About Garmin International, Inc. Garmin International, Inc. is a subsidiary of Garmin Ltd. (NYSE: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin is a registered trademark and Enduro, Garmin Connect, Power Sapphire and QuickFit are trademarks of Garmin Ltd. or its subsidiaries. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.

Notice on Forward-Looking Statements:
This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 27, 2025, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983). Copies of such Form 10-K are available at https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

MEDIA CONTACTS:
Elliott Scott
913-397-8200
[email protected]

SOURCE Garmin International, Inc.

New SailPoint Human Fabric capabilities and SailPoint IdentityIQ 9.0 release deliver security and governance built for enterprise scale, ensuring no customer is left behind in their security evolution  | Source: SailPoint Technologies, Inc.

AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Today at its annual flagship conference, Navigate, SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, announced a significant modernization across its entire identity platform. The company unveiled new enterprise-scale capabilities for SailPoint Human Fabric and the release of IdentityIQ 9.0, a major update to its on-premises solution. These updates demonstrate a unified commitment to modernizing identity security for every customer, whether in the cloud, on-premises, or in a hybrid environment.

The announcements address a challenge facing the industry as a whole: most identity governance infrastructure can't keep pace with how enterprises operate today. SailPoint is closing that gap with substantive updates that re-platform core services for scale and strengthen governance, not simple UI refreshes.

Chandra Gnanasambandam, EVP of Product and Chief Technology Officer at SailPoint, said:
"Most vendors ask their customers to choose between a growth story or a stewardship story, but the reality of the modern enterprise is not that simple. Today, we are delivering on both fronts. We are advancing the frontier of cloud identity security with Human Fabric while also demonstrating our commitment to the customers who rely on IdentityIQ for identity security. This is one modernization effort on two fronts, ensuring every customer has a path forward without compromise.”

Governance built for enterprise scale: The SailPoint Human Fabric
SailPoint announced three new major updates for Human Fabric, its cloud-native identity security product, designed to operate at enterprise scale:

Access certifications enhancements: A completely re-platformed certification engine built to handle enterprise-scale access reviews without record limits or data delays. The new engine removes the need for administrators to manually split large campaigns and includes a faster, more intuitive reviewer interface and cryptographic, GxP-compliant sign-off for regulated industries.Proactive Separation of Duties (SoD): Moving beyond after-the-fact alerting, SailPoint’s enhanced SoD engine provides real-time evaluation that proactively blocks toxic access combinations at the moment of request. It uniquely flags conflicts created by other pending requests still in-flight, preventing violations before they occur.Conversational Access Requests: A new AI-powered agent allows users to make access requests in natural language directly from their chat tools. With support for custom forms, employees can provide necessary business justifications and compliance details seamlessly within the chat flow.
No customer left behind: IdentityIQ 9.0
For customers with extensive data residency requirements, strict regulatory constraints, or deeply customized programs, SailPoint is delivering IdentityIQ 9.0. The release provides a parallel modernization path for hybrid and on-premises deployments, centered on three pillars: a stronger governance, including granular, time-based access for roles and entitlements, and a rebuilt technical foundation running on modern application servers, with a refreshed user experience that streamlines access reviews and application definition.

Critically, SailPoint is also offering an automated upgrade tool with the release. This utility scans a customer’s environment and automates much of the manual work required to update, addressing the primary risk that stalls on-premises upgrades and proving that customers can confidently evolve their existing deployments.

Learn more about all the new products announced today at Navigate here.

About SailPoint
SailPoint (Nasdaq: SAIL) is defining the new era of adaptive identity security. In a world where non-human identities now significantly outnumber humans, our AI-powered platform unifies identity, security, and data intelligence to protect today’s enterprise from advanced identity-based threats. We deliver the identity solution that spans both the breadth of identities and the depth of context needed to drive real-time access with confidence. Built on principles like zero-standing privilege and contextualized risk, our SailPoint platform transforms identity from a point of vulnerability into a powerful security advantage. Trusted by many of the world's leading organizations, SailPoint secures the enterprise with intelligent, autonomous identity security.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to SailPoint’s expectations regarding announcements made at Navigate. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “expects,” “plans,” “anticipates,” “could,” “would,” “plan to,” “intend to,” “believe,” or “goal” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are not guarantees of future performance, but are based on management's current expectations, assumptions and beliefs concerning future developments and their potential effect on us, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Our expectations expressed or implied in these forward-looking statements may not turn out to be correct. The development, release, and timing of any features or functionality described for SailPoint’s products that are not currently available remain at SailPoint’s sole discretion on a when, and if available, basis, may not be delivered at all and should not be relied on in making a purchasing decision, and could be materially different from our expectations because of various risks.

Important factors, some of which are beyond our control, that could cause actual results to differ materially from our historical results or those expressed or implied by these forward-looking statements include the following: our ability to deepen our relationships with existing customers; the growth in the market for identity security solutions; our ability to maintain successful relationships with each of our partners; our ability to compete successfully against current and future competitors; the increasing complexity of our operations; our ability to maintain and enhance our brand or reputation as an industry leader and innovator; unfavorable conditions in our industry or the global economy; our ability to successfully introduce, use, and integrate artificial intelligence (AI) with our solutions; breaches in our security, cyber attacks, or other cyber risks; interruptions, outages, or other disruptions affecting the delivery of our SaaS solution or any of the third-party cloud-based systems that we use in our operations; our ability to adapt and respond to rapidly changing technology, industry standards, regulations, or customer needs, requirements, or preferences; real or perceived errors, failures, or disruptions in our platform or solutions; and the ability of our platform and solutions to effectively interoperate with our customers’ existing or future IT infrastructures.

More information on these risks and other potential factors that could affect our financial results is included in our reports and other documents filed with the Securities and Exchange Commission including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in our most recently filed Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date as of which such statement is made, and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events, or otherwise.

The development, release, and timing of any features, functionality, capabilities, or services described for SailPoint's products that are not currently available remain at SailPoint's sole discretion on a when, and if, available basis and may not be delivered at all and must not be relied on in making a purchasing or investing decision.

Media relations for SailPoint
Shannon Paulk
Sr. Manager, Corporate Communications
303-748-2275
[email protected]

New York, New York--(Newsfile Corp. - October 6, 2026) - NANO Nuclear Energy Inc. (NASDAQ: NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear micro modular reactor and technology company focused on developing clean energy solutions, nuclear fuel cycle capabilities and nuclear transportation solutions, today announced that it has hired Jennifer Charlton, Ph.D., as its Vice President of Fuel Technology.

Dr. Charlton brings nearly two decades of experience in nuclear materials, uranium processing, fuel-cycle technology, and advanced manufacturing to NANO Nuclear. Prior to joining NANO Nuclear, Dr. Charlton held several senior technical and leadership positions at the Y-12 National Security Complex. Notably, she served as Chief Scientist and U.S. Lead for Nuclear Material Verification, leading technical initiatives and providing comprehensive technical expertise across the nuclear fuel cycle, from uranium mining and milling through conversion, enrichment, fuel fabrication, and finished fuel and weapons component operations.

"NANO Nuclear's strategic focus on building capabilities across key areas of the nuclear fuel cycle is an important part of supporting its long-term microreactor deployment strategy," said Jennifer Charlton, Ph.D., Vice President of Fuel Technology of NANO Nuclear Energy. "I'm excited to join the team at this important stage of its growth and leverage my experience leading complex technical initiatives to help advance this strategy and strengthen NANO Nuclear's capabilities across the fuel cycle."

Figure 1 - NANO Nuclear Energy Hires Former Y-12 Leader and Nuclear Fuel Cycle Expert, Jennifer Charlton Ph.D. as its Vice President of Fuel Technology.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11703/317616_08bb19ec343c59a3_002full.jpg

Dr. Charlton earned a Ph.D. in Chemistry from the University of Tennessee, a Bachelor of Science in Chemistry from the University of North Florida, and an Associate of Arts from Florida State College. Her graduate research encompassed automated radiochemical separations, nanofabrication, surface-enhanced spectroscopy, mass spectrometry, instrumentation development, nuclear forensics, trace-level materials analysis, and materials characterization.

"It is a pleasure to welcome Dr. Charlton to the NANO Nuclear team," said Jay Yu, Founder and Chairman of NANO Nuclear Energy. "Her addition marks another step towards ensuring that we have the right personnel to oversee NANO Nuclear's long-term strategic focus on vertical integration. Her experience within the Y-12 National Security Complex will be invaluable as we look to expand our capabilities across the nuclear fuel cycle."

Dr. Charlton joins a growing list of former senior nuclear leaders and builds on NANO Nuclear's recently announced addition of Marylin Diaz to support the Company's expansion across the nuclear fuel cycle. In her role as Vice President of Fuel Technology, Dr. Charlton will be responsible for evaluating opportunities to expand NANO Nuclear's capabilities across the nuclear fuel cycle and leading the design, engineering, and development of related technologies, with a focus on the uranium conversion, deconversion, and fuel fabrication processes. She will also provide technical expertise to inform strategic decisions regarding NANO Nuclear's broader vertical integration strategy in support of future advanced reactor deployments and nuclear logistics activities.

"As our core, proprietary technology, the KRONOS MMR™ Energy System, continues along its development pathway, we are working to expand across the nuclear fuel cycle to help de-risk the marketplace as well as support the energy sovereignty of the United States," said James Walker, Chief Executive Officer of NANO Nuclear Energy. "Dr. Charlton's appointment is a key step in that effort, and I am delighted to welcome her to the Company. I believe that Dr. Charlton's addition, as well as her experience and knowledge of the inner workings of the fuel cycle will prove to be incredibly important as we continue to put together the building blocks for our next stages of growth."

About NANO Nuclear Energy, Inc.

NANO Nuclear Energy Inc. (NASDAQ: NNE) is a North American advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel supply chain, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services.

Led by a world-class nuclear engineering team, NANO Nuclear's reactor products in development include the proprietary KRONOS MMR™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign, the ZEUS™ system, a portable solid core battery reactor, and the space focused, portable LOKI MMR™ system, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.

Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, bolstered by the May 2026 acquisition of Secured Transportation Services (STS), is led by former executives from the largest transportation company in the world and provides nuclear engineering and materials transport services in the U.S. and globally. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy.

HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear's own microreactors as well as the broader advanced nuclear reactor industry.

NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear's developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS' initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon's surface.

Cautionary Note Regarding Forward Looking Statements

This news release and statements of NANO Nuclear's management and collaborators in connection with this news release contain or may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "explore," "plans", "aim," "goal," "believes", "potential", "future," "will", "should", "could", "would" or "may" or derivations of these words and other words of similar meaning about the future, although forward-looking statements could be denoted by other terms as well. In this press release, forward-looking statements relate to the anticipated benefits of Dr. Charlton joining the Company, as well as the Company's vertical integration and other operational plans and goals. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to, risks associated with conditions to closing the asset purchase agreement, which may not be satisfied, including for reasons beyond NANO Nuclear's control, as well as the following: (i) risks related to our U.S. Department of Energy ("DOE"), U.S. Nuclear Regulatory Commission ("NRC"), Canadian Nuclear Safety Commission ("CNSC") or related state or other U.S. or non-U.S nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complementary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) risks related to our ability to obtain key vendor, technology and customer contracts and the significant funding necessary to execute on our business plan, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the U.S. Department of Energy, and the NRC, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, and (vi) similar risks and uncertainties associated with the operating a developing business a highly regulated, competitive and rapidly evolving industry, including that our plans may change and we may use our cash on hand faster or in different ways than anticipated as our business requires. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/317616

Source: NANO Nuclear Energy Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

 | Source: Galectin Therapeutics Inc.

NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b trials of belapectin for the treatment of MASH cirrhosis and portal hypertension. The meeting will be held November 5-9, 2026, in Denver, Colorado.

In addition, the Company also announced today that it has submitted a registrational protocol for the Phase 3 trial of belapectin for the prevention of disease progression in patients with MASH cirrhosis and portal hypertension to the U.S. Food and Drug Administration (FDA).

“We are excited to have our ANTICIPATE-NASH analysis selected for oral presentation and the recognition of our Baveno and ELF analysis as a Poster of Distinction. These selections reflect not only the depth of the NAVIGATE trial datasets but also underscores the importance of non-invasive assessments in diagnosis of portal hypertension in patients with MASH cirrhosis who are at increased risk of developing serious complications such as varices. This represents the fourth consecutive major liver meeting where the Company has been selected for an oral presentation, and I want to thank our entire team led by Dr. Khurram Jamil, our Chief Medical Officer, for their efforts in this achievement. We have also submitted the registrational Phase 3 protocol, an important step forward in the advancement of our belapectin program for patients who today have no approved treatment options,” said Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics.

Presentation Details
Oral Presentation

Title: ANTICIPATE-NASH Risk Stratification Predicts Variceal Development in Compensated MASH Cirrhosis: Results from the NAVIGATE Trial
Publication Number: 0253
Presenter: Naim Alkhouri, M.D., FAASLD
Date & time: November 8, 2026, 9:15 am - 9:30 am MST

Poster Presentations

Poster of Distinction:
Title: Baseline Baveno Portal Hypertension and ELF Risk Stratification Predict Variceal Development in Compensated MASH Cirrhosis: Findings from the NAVIGATE Trial
Session: MASLD/MASH - Therapeutics: New Agents and Approved/Available Agents
Presenter: Naim Alkhouri, M.D., FAASLD
Date & time: November 7, 2026 at 12:00 pm - 1:00 pm MST

Title: Correlation of Baveno VII and ANTICIPATE-NASH Noninvasive Models with HVPG in Patients with MASH Cirrhosis: Findings from a Phase 2b Belapectin Trial
Session: Portal Hypertension and Other Complications of Cirrhosis
Presenter: Naim Alkhouri, M.D., FAASLD
Date & time: November 5, 2026 at 12:00 pm - 1:00 pm MST

The presentations will be available for viewing by AASLD attendees and will be posted on our website under the “Events & Presentations” page shortly after the congress.

        About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and portal hypertension, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect”, “look forward”, “believe”, “hope” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not produce positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.

Company Contact:

Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]

Investors Relations Contacts:
Kevin Gardner
[email protected] 

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.

A federal judge just cleared billions in ad-tech damages claims against Google to proceed to trial, where antitrust law would automatically multiply whatever a jury awards. But the real threat to Alphabet shareholders may not be this case at all.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

On September 30, 2026, a federal judge in New York signed an 88-page opinion. The opinion denied most of Google’s motions to dismiss advertising-technology damages claims. That leaves about $3.2 billion in claims for a jury to hear.

The ruling was first reported on October 1, 2026. Alphabet (NASDAQ:GOOG | GOOG Price Prediction, NASDAQ:GOOGL) shares closed the most recent session at $346.47, up 0.86%.

The dollar figure is what plaintiffs seek, and US antitrust law automatically triples whatever a jury awards. No trial date has been set.

Shareholders face a key question. Can a bill this size hurt a company worth $4.2 trillion, or is the bigger risk the copycat claims that may follow?

What the Court Allowed and What It Dismissed Plaintiffs claim about $1.72 billion for a certified class of about 5,000 publishers. They also claim about $900 million for USA Today Co. (NYSE:TDAY), formerly Gannett, and about $600 million for the Daily Mail.

USA Today Co.’s chief legal counsel spoke about the ruling. He said it lets the company go after “$1 billion in worldwide damages (before trebling under the antitrust laws)”. That $1 billion figure is the company’s own framing. The opinion shows the smaller amount.

Google also won some ground. The court dismissed claims from publishers who used other advertising tools, along with a separate $479 million claim. Google said it will “defend the rest in court.”

No damages have been awarded. If a jury granted the full amount, trebling (the automatic tripling) would push it to a theoretical $9.6 billion.

How Big $9.6 Billion Is Against Alphabet Alphabet earned $40.77 billion in operating income in the second quarter of 2026 alone, on revenue of $119.80 billion. Even the tripled maximum is smaller than one quarter of operating profit.

Alphabet absorbed a $3.5 billion European Commission competition fine in its third-quarter 2025 results, which shows the company has paid penalties of this scale before.

Cash flow is where a large payment would matter. Free cash flow was -$5.855 billion in the second quarter because capital spending reached $44.924 billion.

Why Publisher Claims Are Harder to Escape A 2025 ruling in Virginia found that Google illegally monopolized parts of the ad-tech market. That finding carries over to New York, which is why the damages phase is under way. On September 2, 2026, a judge turned down a request to break up the ad business and ordered operational changes instead.

Harm from search antitrust spreads across consumers and is hard to price, but publishers are direct customers with measurable lost revenue, so a court can calculate their damages.

That makes this case a model. Other publishers can copy the structure of one large class plus two big individual plaintiffs. Future claims may matter more than this case.

What the Lawsuit Means for Alphabet’s Valuation The market’s calm looks correct. The stock trades at 23x forward earnings, and analysts hold 13 strong buys and 43 buys, with 0 sells.

For now, the case is a cost Alphabet can absorb. It would become a reason to rethink the stock only if copycat suits multiplied the exposure while free cash flow stayed negative. Then legal payments would be stacked on long-term debt that has already grown to $98.2 billion.

The business case outweighs the litigation. Google Cloud grew 82% in the second quarter, and that growth matters far more to the valuation than this litigation does.

Watch for a trial date on the schedule and the legal reserve reported with third-quarter results expected October 28, 2026. Also watch whether the stock holds its 200-day moving average of $338.92.

Contact [email protected] for any questions or corrections.